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Abstract
This dissertation covers a variety of the genetic and molecular abnormalities of lung adenocarcinoma
with an emphasis on STK11 loss and its implications on immunotherapy response. Given that lung
cancer is the leading cancer killer, novel therapies are in great demand. In particular, immunotherapy
has shown some of the most promise in the last decade but remains limited due to nearly 80% of
patients not significantly responding. This dissertation aims to molecularly characterize lung
adenocarcinoma while attempting to explain the reason why patients with STK11 loss do not respond to
immunotherapy.
In the first chapter we discuss the relationship between ancestry and mutational frequency in lung
adenocarcinoma. We performed next generation sequencing on over 100 tumors from Hispanic
patients. From whole blood, we calculated ancestry using a panel of single nucleotide polymorphisms.
Our analysis revealed that Indigenous American ancestry is highly associated with an increased rate of
EGFR mutations despite smoking status. Further studies will be needed to determine whether this
change in frequency can be attributed to the environment or if polymorphisms associated with this
ancestry can predispose patients to the acquisition of lung cancers driven by EGFR.
Chapter 2 is focused on the classification and characterization of patients with mutations in STK11. First,
we developed a novel signature for the prediction of STK11 loss of function in lung adenocarcinoma
patients. We further describe the inverse relationship of the polyamine pathway with gene expression
markers of immune response suggesting that polyamines may be the result of immune suppression in
patients with STK11 loss of function. Finally, using LC-MS we show that patients with loss of function in
STK11 upregulate putrescine and GABA amongst other metabolites. This reveals that not only do
xi

patients upregulate genes regulating polyamine metabolism (ODC1) but that the metabolites
downstream of its control are upregulated. These data also suggest a non-canonical utilization of
putrescine for the synthesis of GABA.
Chapter 3 highlights the limitations of studying STK11 loss in vitro through its impact on cell lineage
identity. We reveal that cell line, mouse models, and patient derived xenografts of STK11 loss
unanimously lose their marker of cell lineage (NKX2-1). In addition to this loss in cell lineage, a small
subset of patient tumors that lose NKX2-1 also lose hallmarks of immune modulation through
inflammatory signaling and polyamine metabolism. These patient tumors that lack NKX2-1 have similar
genetic changes as ex vivo models of STK11 loss suggesting that we are not accurately studying STK11
loss as it occurs in a majority of patients.
Chapter 4 is a description of in vitro experiments performed using cell lines with a small report of in vivo
biomarkers of STK11 loss. We restore STK11 expression in 3 cell lines lacking STK11 function: A549,
NCIH1437, and NCIH1944. We confirm that the addition of STK11 to these cell lines did not alter ODC1
expression or other patient specific biomarkers of STK11 loss. We further attempted to recapture the
patient tumor phenotype of STK11 loss through the modification of metabolic stress. Other
experiments focused on sensitivities or resistance as a result of STK11 loss. We conclude by displaying
that KIT can be used as a biomarker for STK11 loss in vivo.
Chapter 5 is a molecular characterization of lung adenocarcinoma. We performed untargeted LC-MS on
123 patients from our MLOS cohort for proteins and metabolites. We analyzed the relationship
between networks of protein, metabolite, and gene expression. We then molecularly characterized this
cohort by mutations in STK11, EGFR, KRAS, TP53, and KEAP in addition to by two immune signatures for
inflammatory and interferon gamma response. Finally, using the overall survival data in this cohort we

xii

identified novel metabolite, protein, and gene expression networks that can be used in patient
prognosis.

xiii

Introduction

Lung Cancer Epidemiology and Statistics
As of 2018, lung cancer is the leading killer amongst all cancer types and the second most commonly
occurring [1] (Figure I.1). Global estimates of lung cancer cases in 2012 were over 1.8 million new cases
year and 1.6 million deaths in the same year, increasing from 1.6 million cases and 1.4 million deaths in
2009. In 2018 in the United States it is estimated that 234,030 people will be diagnosed, 121,680 men
and 112,350 women. In the same year it is estimated to account for 25% of all cancer related deaths
and has one of the worst survival rates. 5-year overall survival for all combined stages increased only
from 12% in 1975 to 18% in 2003. Advanced stages have a 5-year survival of roughly 5% [2]. These data
highlight the importance and urgency for the discovery of novel therapies for the treatment of this
malignancy.
Lung cancer is more commonly associated with old age with the median diagnosis for both men and
women being 70 years of age [1, 2]. Only 10 percent of lung cancer diagnoses are found in patients of
less than 55 years and are likely attributed to genetic predisposition [1, 2]. Data suggests that nonsmoking related cases of cancer are elevated in woman compared to men, with women harboring
significantly higher rates of EGFR mutations [3, 4]. Tobacco smoke is by far the greatest single risk factor
for lung cancer with over 90% of all lung cancers being caused by smoking.
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Figure I.1 Cancer incidence and mortality by gender
Lung Pathological and Molecular classification
Pathologic diagnosis is of great importance for proper cancer treatment and care. Histological subtyping
allows for more personalized treatment through the classification of lung cancer into distinct subtypes
based upon their cell of origin. Our increase in knowledge about these subtypes has given insight into
the prognosis, genetic drivers, and likelihood of various treatment responses. Lung cancer histological
subtypes include adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and large cell
carcinoma [1]. The first tier of lung cancer classification divides lung cancer into either non-small cell or
small cell, with non-small cell encompassing squamous, adenocarcinoma, and large cell carcinoma [5].
The most common subtype of lung cancer is adenocarcinoma, comprising roughly 40% of all lung
cancers. Squamous cell carcinoma makes up roughly 30% followed by small cell and large cell carcinoma
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at 15% and 5% respectively (Figure I.2). To further the complexity of this classification even further,
each histological subtyping of lung cancer can be classified by driver mutations or pathway aberration.

Figure I.2 Frequency of pathological subtypes of lung cancer
Adenocarcinoma
Lung Adenocarcinoma is the most commonly occurring histological subtype of lung cancer, and even
more enriched in frequency among non-smokers [6, 7]. The cell of origin of lung adenocarcinoma is the
type II pneumocyte or alveolar type II cell [8, 9]. These cells are responsible for mediating gas exchange
and response to lung injury through the secretion of pulmonary surfactants. Pathologically they are
characterized by having high expression of the marker NKX2-1 also known as thyroid transcription factor
1 (TTF1). Similarly to squamous cell carcinoma the most commonly occurring mutation is TP53 at a rate
of 65%. However, unlike squamous cell cancers most tumors harbor mutations at high frequency in
3

oncogenic drivers KRAS (35%) or EGFR (25%) with KRAS being most common amongst smokers and EGFR
most common amongst non-smokers [10]. Other mutations in tumor suppressors such as STK11 also
occur at a high rate of 30% and KEAP1 (20%). Most patients have a mutation in one of the preceding
genes, making lung adenocarcinoma more readily classifiable, but nonetheless a challenging one to
treat. Targeted molecular therapy exists for mutations in EGFR but other mutations have proven to be
much less actionable [11, 12]. There have been several attempts at targeted therapy for KRAS pathway
activation [13-15]. Increased understanding into these genetic drivers of cancer initiation and
progression will be crucial in increasing patient survival.
Squamous cell carcinoma
Squamous cell carcinoma is characterized by the expression of cytokeratins and formation of keratin
pearls [1]. Most commonly associated with being a central lung tumor, these cells have basal like
properties and commonly express the genetic markers TP63, KRT5, and SOX2 [16]. The most commonly
occurring somatic mutation in squamous cell carcinoma is the tumor suppressor TP53 which occurs at a
frequency of 65%. DNA level amplifications are seen in genes: FGFR1, SOX, PIK3CA, MDM2, PDGFRA, and
MET. Other important somatic mutations that occur at a 1-10% frequency include: MDM2, PDGFRA,
MET, NRF2, PTEN, EPHA2, STK11, AKT, EGFR, DDR2, and PTEN [17]. Due to the fact that many different
mutations occur at low frequency in squamous cell carcinoma, it is much more difficult to classify these
tumors into straightforward treatment regimes, as in the case adenocarcinoma. However, attempts
have relied on the utilization of gene expression as a representation of downstream signaling in order to
target pathways rather than specific somatic mutations [17, 18].
Small Cell Carcinoma
Small cell carcinoma is an extremely aggressive cancer accounting for roughly 15% of all lung cancers. 5year overall survival is between 5% and 8% [1]. These cells are also thought to originate from
4

neuroendocrine cells. The most common genetic alterations occur in TP53, RB1, PTEN, and many others
[19]. This histology is often associated with MYC activation, and expresses master regulators ASCL1 and
NEUROD1.
Large Cell Carcinoma
Large cell carcinoma is the rarest subtype found at a frequency of roughly 5% of all lung cancers. Large
cell carcinoma is most commonly diagnosed when no other diagnosis can be made [1]. A subset of large
cell carcinomas is classified as large cell neuroendocrine carcinoma, and arises from neuroendocrine
cells. In general, not as much is known about this subtype of lung cancer.
Alveolar type I and II pneumocytes
Type I pneumocytes (ATI) also populate the lung, but they are not capable of self-replication as they lack
cellular organelles. They represent roughly 8% of the total cells by number, yet make up almost 90-95%
of the lung surface. Type II pneumocytes (ATII) on the other hand, comprise only 5% of the lung alveolar
surface but 15% of the total cell number [9]. These cells are both functionally and metabolically
differentiated epithelium. It has been noted that dedifferentiation and loss of the ATII phenotype to an
ATI phenotype has occurred when studied in vitro [9, 20]. This provides a severe limitation to the study
of relevant lung biology, especially in the context of oncology [20].

The ATII cell lineage gives rise to lung adenocarcinoma and are characterized by the expression of (TTF1
or NKX2-1) [21]. These cells have unique metabolic characteristics, as they produce and secrete lipid
surfactants, mediate the innate immunity, and control inflammation and repair of the lung [8].
Surfactants (gene symbols SFTP A-D) allow for low surface tension and optimal gas exchange in the lung,
and have been shown to mediate inflammation and fight infection in the lung. In response to infection
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ATII cells can secrete cytokines and chemokines capable of recruiting and activating immune cells such
as IL1, TNF, IL-6, CXCL1, CXCL5, CXCL8, and even type I interferons.
NKX2-1
The NKX2-1 transcription factor is a lineage distinguishing biomarker of lung adenocarcinoma[21]. Much
controversy surrounds this gene as it has been described as both an oncogene and tumor suppressor
dependent upon context [22, 23]. A publication highlighted the ability of NKX2-1 to function as a
repressor of malignant progression in KRAS/TP53 double mutant mouse models [24]. Mutations in
NKX2-1 result in a condition known as brain-lung-thyroid disease, a rare familial disorder descriptive of
the organs in which NKX2-1 expression is abundant [25]. Patients with this condition have learning
difficulty, psychosis, chorea, dystonia, and developmental delay.
NKX2-1 in the lung
In the lung, NKX2-1 has been shown to regulate the transcription of pulmonary surfactants [26]. Other
studies have displayed the duality of NKX2-1 to regulate inflammatory signaling through NF-kappaB in a
TP53 dependent manner [27]. Further, NKX2-1 has a role in repressing latent gastric differentiation in
lung adenocarcinoma, suggesting that the lung lies further down the embryonic lineage tree from the
gastric endoderm [28]. These gastric enzymes were regulated by the transcription factors FOXA1 and
FOXA2 in the absence of NKX2-1, as NKX2-1 is a repressor to their functionality [29]. Other studies have
elucidated NKX2-1’s role in determining the shape of the immune microenvironment through the
balance of the expression of SOX2 and NKX2-1 in lung cells [30].
Neuroendocrine cells
Neuroendocrine cells are a very rare and innervated epithelial cell type. In fact, they are the only
innervated cell type in the lung airway, and release a number of neuropeptides, amines, and
neurotransmitters in response to changes in oxygen availability and other stimuli [31]. They often are
6

found in clusters rather than single cell populations called neuroepithelial bodies [32]. Several diseases
have been linked to aberration in these cell types such as: chronic obstructive pulmonary disease, cystic
fibrosis, and asthma [33, 34]. Neuroendocrine cells upregulate calcitonin related gene peptides such as
CALCA and can have significant impact on immune cell recruitment and function. In fact, these cell types
have been described as rheostats of the airway, capable of translating environmental stimulus into
immune responses.
Immunotherapy
Immunotherapy has shown some of the most promising results in modern day cancer therapy,
increasing the survival rate of a number of different cancers [35]. Given the high mutation burden and
subsequently high quantity of neo-antigens in lung cancer, immunotherapy has shown efficacy in this
cancer type. However, this efficacy remains limited, as only 20% of all patients respond [36, 37]. The
main function of immunotherapy is to activate an otherwise anergic immune response, often an end
product of a tumors adaptive ability to evade the immune system. Mechanistically-informed
immunotherapy focuses on inactivation of either inhibitory receptors on the immune cells, or inhibitor
ligands on the tumor. The most common receptor-ligand pairs that are inactivated include CTLA4, which
binds the CD80 costimulatory receptor, or programmed cell death receptor/ligand PD-1/PD-L1 [38]
(Figure I.3). Anti PD-1 therapeutic antibodies include Nivolumab and Pembrolizumab, while anti PD-L1
antibodies include Durvalumab, Atezolizumab, and Avelumab. These receptors are most commonly
found of CD8+ cytotoxic T lymphocytes, which are attributed to having the largest anti-tumor immune
response. While some tumors overexpress inhibitory ligands, others find novel ways of evading the
immune response by undiscovered mechanisms. Source for figure below explaining T-cell activation and
suppression [37].
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Figure I.3 T-cell activation and effector function suppression through PD-1 and PD-L1
STK11 Function
STK11 (serine threonine kinase 11), also known as LKB1 (liver kinase B1), is located on the p13 arm of
chromosome 19. STK11 forms a complex with two additional proteins: STRAD and MO25, who when
bound, re-localize from the nucleus to the cytoplasm [39]. The two most common histological subtypes
for STK11 mutations are large cell neuroendocrine carcinoma and lung adenocarcinoma, both with a
frequency of around 30% of tumors [40]. STK11 is most commonly known for its kinase activity and
ability to phosphorylate and activate AMPK [41]. In addition to its role in the phosphorylation of AMPK,
it has also been shown to activate over 14 other downstream kinases. Previously, STK11 has been linked
to the regulation of cell polarity [42], metabolic response [43, 44] , methylation [45], apoptosis [46], and
metastatic potential . Only recently has STK11 been found to be associated with a decrease in immune
infiltration and response to immunotherapy [47-49]. Interestingly, mutations in STK11 occur in other
cancers such as ovarian, breast, skin, and gastrointestinal but none of them occur at rates exceeding 5%.
Even amongst lung cancers it is only lung adenocarcinoma and neuroendocrine large cell carcinoma with
mutation rates above 5% frequency. This strongly suggests that there is a favorable selective pressure
for STK11 loss in cells that give rise to these cell lineages.
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Figure I.4 STK11 function and signaling
Heterozygous loss of STK11 also gives rise to a condition known as Peutz-Jeghers syndrome (PJS) [50,
51]. Interestingly, those affected by this condition are likely to develop hamartomatous polyps in the
gastrointestinal tract. In addition to GI polyps, children will often develop dark colored spots on the lips
and inner mouth. People with heterozygous loss of STK11 are also at a much greater risk of cancer.
Genetically, mutations in STK11 have significant co-occurrence with mutations in KRAS (Kirstein Rat
Sarcoma viral oncogene) and KEAP1 (Kelch like ECH associated protein). KRAS is an oncogene capable of
constitutively activating MYC and proliferative signaling [52-54]. KEAP1 functions as a binding partner to
9

NRF2 and serves as a repressor of NRF2 nuclear localization and transcriptional activity [55, 56]. NRF2
transcription results in activation of the oxidative stress response. Additionally, STK11 has been shown
to serve as a suppressor of MYC activity [57-60]. Activation of KRAS with loss of STK11 could potentially
result in the synergistic upregulation of MYC.
STK11 and metabolic control

STK11 functions as a mediator of metabolic stress through the activation and phosphorylation of (AMP
active protein kinase) AMPK [44]. Reduced energy availability shifts the balance of this signaling
pathway through an increase in AMP/ATP ratio. Activation of AMPK results in the induction of
autophagy and energy sensing pathways, inhibiting Mechanistic Target of Rapamycin mTOR (Figure I.4).
These two pathways shift metabolic signaling between catabolic (AMPK) and anabolic (mTOR).
Deficiency in STK11 allows tumors to eliminate stress signaling and allow for more rapid, anabolic
growth even under periods of limited nutrient availability. Additionally, during periods of prolonged
starvation or autophagic signaling, apoptotic signaling can occur [43]. Other studies have focused on
STK11’s ability to upregulate carbamoyl phosphate synthetase 1 (CPS1), the first rate limiting step of the
urea cycle [61, 62]. CPS1 knockdown resulted in reduced growth and nucleic acid biosynthesis,
suggesting alterative mechanisms of biomass generation during metabolic stress. STK11 deficiency has
also been linked to glutamine addiction, one of the most abundant amino acids [44, 63, 64]. STK11 loss
of function may allow for a shift in energy utilization while sequestering growth inhibitory signaling that
would normally be the result of metabolic stress.
STK11 and immune suppression
Perhaps the most recently discovered impact of STK11 loss lies in its relationship to the immune system.
Patient tumors harboring a mutation in STK11 have been shown to have significantly reduced levels of
PD-L1 [47, 65]. Gene expression studies have also elucidated a decrease in inflammatory and interferon
10

related signaling. Additionally, these same tumors also have shown reductions in T-cell lineage markers
through gene expression and immunohistochemistry, specifically in the CD4+ helper and CD8+ cytotoxic
subtypes [53, 66]. Taken together, this suggests that PD-L1 is absent in these tumors due to an
alternative evasion of the immune response by way of cytotoxic immune cell recruitment. Not only do
these tumors show a decrease in immune response but they also show little to no response to
immunotherapy [48, 49]. Novel therapies for the molecular targeting of tumors with STK11 loss is of
great need, especially in the context of the reactivation of the immune response. The direct cause of
STK11 mediated immune suppression remains to be known.
STK11, NKX2-1, and their impact on differentiation through TP53
Mechanistic studies have revealed that STK11 is directly upregulated through TP53 signaling mediated
by NKX2-1[67]. However, in cells with mutated TP53 the opposite was true. In this context, STK11 was
downregulated by NKX2-1 through the inhibition of SP1 binding to the STK11 promoter. This highlights
the intricate role that TP53 signaling plays in the cross talk between NKX2-1 and STK11. Prognosis of
patients in TP53 wildtype tumors was worse for low NKX2-1/low STK11 compared to high NKX2-1/high
STK11. In patients with TP53 mutant tumors, worse prognosis was for patients with high NKX2-1/low
STK11 compared to low NKX2-1/high STK11. This suggests the intricate role and cross talk of STK11 in
the context of TP53 function and cell lineage transcription factor NKX2-1.
Polyamines
Polyamines are positively charged organic compounds that contain more than two amino groups [68].
Found in all forms of life, they are known to bind to DNA and impact a number of cellular processes such
as transcription, translation, autophagy, oxidative stress, and inflammation [69-72]. Due to this, they
are one of the most delicately and intricately regulated of all mammalian pathways and their regulatory
genes have transcriptional and translational half lives in the range of 10-30 minutes. In fact, ODC1 is
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regulated through the complex balance of antizymes and antizyme inhibitors, which target ODC1 for
degradation through the 26S proteasome. Additionally, they have also been known to play a role in ion
channel regulation and synaptic transmission through the NMDA and AMPA receptors. In addition to
their neurological role they have also been known to protect the cell in periods of oxidative stress by
serving as scavengers of reactive oxygen species. The rate limiting step of polyamine synthesis is also
the first one and is accomplished through the decarboxylation of ornithine to putrescine by ODC1
(ornithine decarboxylase) (Figure I.5). Interestingly, just as KRAS activation and STK11 loss activate MYC,
ODC1 is a key transcriptional target of MYC [73, 74]. Putrescine is further converted to spermidine by
spermidine synthase (SRM) and spermidine to spermine by spermine synthase (SMS). An irreversible
inhibitor of ODC1 has been developed called difluoromethylornithine (DFMO) and functions as an
inhibitor of polyamine synthesis [68, 75-78]. The polyamine pathway has been strongly linked to
immune suppression and its inhibition through DFMO has been shown to reverse this phenotype [79,
80].

Figure I.5 Polyamine pathway
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Polyamines play a large role in translation, through the regulation of it comes as no surprise that they
are an integral part of methionine salvage, the amino acid responsible for translational initiation.
Through S-adenosyl-L-methionine (SAM), both spermidine and spermine are given an aminopropyl
group through putrescine and spermidine respectively [81, 82]. SAM is largely responsible for serving as
a methyl donor and alterations in its abundance can impact epigenetic control through DNA, histone,
and protein methylation [83, 84].
Nitrogen metabolism, vitamin B6 (pyridoxal), and the urea cycle
As the most abundant gas in our atmosphere, nitrogen plays a large role in life and especially cancer
[85]. It is involved in nearly every aspect of biology from the synthesis of nucleic acids to amino acids.
However, the simplest form of nitrogen is ammonia and is very toxic, especially neurologically. Taking
place in the liver, the urea cycle, processes ammonia and excretes it in the form of urea [86] (Figure I.6).
Primarily, excess ammonia is formed through the utilization of amino acids as energy substrates through
the removal of an amino group, leaving the remaining carbon backbone. Mostly all deamination
(removal of amino group) and transamination (transfer of amino group) reactions require vitamin B6
(pyridoxal) as a cofactor [87]. The transfer of amino acids is catalyzed by enzymes such as alanine
aminotransferase GPT2 and ornithine aminotransferase OAT, which help generate glutamine from
alanine and ornithine respectively. Several enzymes play a role in the urea cycle including: arginase
(ARG1), ornithine transcarbamylase (OTC), carbamoyl-phosphate synthase 1 (CPS1), argininosuccinate
synthase (ASS1), and argininosuccinate lyase (ASL) [88, 89]. The first step of the urea cycle is ratelimiting and involves the incorporation of ammonia and bicarbonate to form carbamoyl phosphate and
is catalyzed by CPS1. The next step involves combining carbamoyl phosphate and ornithine to form
citrulline through OTC. Citrulline then reacts with aspartate to form argininosuccinate by ASS1.
Argininosuccinate is then converted to arginine through ASL. Finally, a hydrolysis of arginine forms urea
and ornithine through ARG1.
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Figure I.6 Urea and TCA cycle
Figure from NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue
syndrome [90]
GABA’s background, function, and impact on immune response
GABA function
GABA (gamma-amino butyric acid), is an inhibitory neurotransmitter in the brain [91]. It is essential for
normal brain function, information processing, and even in disease response. Medications that act on
GABA mediated pathways help to treat withdrawals symptoms, epilepsy, anxiety, and even to induce
sedation. It has also been shown to protect neurons during strokes, or acute hypoxia. In addition to
GABA’s role in neurobiology it has also been shown to impact inflammatory response [92]. In fact,
GABAergic agents have been shown to directly impact the function of antigen presenting cells [91, 93].
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Interestingly, GABAergic activity has been linked to cyclic AMP dependent signal transduction pathways
in addition to calcium signaling [94]. GABA receptor activation also reduces cyclic AMP dependent
phosphorylation of STK11 and impacts neuronal polarization [95]. Additionally, GABA treatment on
CD4+ T-cells caused a decrease in proliferation, and inhibited the secretion of over 37 cytokines in a
dose dependent manner [96, 97].
GABA’s synthesis from putrescine and succinate production
In addition to GABA’s role in neurotransmission and immunomodulation, it is most commonly known for
its synthesis from glutamate by the enzyme glutamate decarboxylase (GAD1). However, less known
synthesis of GABA involves the oxidation of either putrescine or n-acetyl putrescine through diamine
oxidase (DAO) or monoamine oxidase (MAOA) respectively [98, 99]. This intermediary step produces
GABA-aldehyde or n-acetyl GABA-aldehyde and through aldehyde dehydrogenases (ALDH3A2) can
further be converted to GABA (Figure I.7). The final step in the utilization of GABA involves the
aminotransferase reaction of GABA to form succinic semi-aldehyde by the enzyme GABA amino
transferase (GABAT). The last step involves succinic acid semi-aldehyde dehydrogenase to form succinic
acid, to be further used in the TCA cycle [100, 101].
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Figure I.7 GABA synthesis from polyamine and recycling through succinate
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Chapter 1: Somatic Mutations and Ancestry Markers
in Hispanic Lung Cancer Patients
Abstract
To address the lack of genomic data from Hispanic/Latino patients with lung cancer, the Latino Lung
Cancer Registry was established to collect patient data and biospecimens from these patients. This
retrospective observational study examined lung cancer tumor samples from 163 Hispanic/Latino
patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including
EGFR, KRAS, STK11, and TP53) and ancestry analysis. Mutation frequencies in this Hispanic/Latino cohort
were compared with those in a similar cohort of non-Hispanic white (NHW) patients and were
correlated with ancestry, sex, smoking status, and tumor histology. Among adenocarcinomas (n=120) in
the Hispanic/Latino cohort, 31% had EGFR mutations, versus 17% in the NHW control group (p < 0.001).
KRAS (20% vs. 38%; p=0.002) and STK11 (8% vs. 16%; p=0.065) mutations occurred at lower frequency,
and mutations in TP53 occurred at similar frequency (46% vs. 40%; p=0.355) in Hispanic/Latino and
NHW patients, respectively. Within the Hispanic cohort, ancestry influenced the rate of TP53 mutations
(p=0.009) and may influence the rate of EGFR, KRAS, and STK11 mutations. Driver mutations in
Hispanic/Latino lung adenocarcinoma patients differ in frequency from those in NHWs associated with
their Indigenous American ancestry. The spectrum of driver mutations needs to be further assessed in
the Hispanic/Latino population.
Introduction
The US Census Bureau projects that the US Hispanic/Latino (H/L) population will reach 119 million by
2060.[102] However, H/Ls represent only 3% of patients characterized in the Cancer Genome Atlas and
Indigenous Americans represent less than 0.5%.[103] Since precision medicine is driven by data that
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primarily represents non-Hispanic white (NHW) patients, there is a significant potential health disparity
for under-represented groups. [104-107] Non-small cell lung cancer (NSCLC), is the leading cause of
cancer death among H/L men and second only to breast cancer in H/L women.[104] In NHW individuals,
half of NSCLC cases have been shown to possess at least one of several known driver mutations,
including alterations in KRAS, EGFR, MET, HER2, BRAF, PIK3CA, AKT1, MAP2K1, ALK, and MEK.[108]
African Americans demonstrate a similar frequency of these mutations. [109] The frequency of EGFR
mutations has been extensively studied for some groups and determined to be approximately 30% for
Asian, 15% for NHW, and 19% to 21% for African American populations.[106, 110] Studies in H/L
individuals have indicated an elevated frequency of EGFR mutations relative to NHWs. [111, 112] Other
common mutations in lung cancer among H/Ls have not been investigated.[113, 114] To address the
lack of molecular data for H/Ls, our group established the Latino Lung Cancer Registry. We describe here
our initial characterization of 163 H/L lung cancer patients.
Results
Patient Characteristics
Table 1.1 summarizes the demographics of the overall cohort and by site of collection. The most
common histology in the cohort was adenocarcinoma (120 [74%]) followed by squamous cell
carcinomas (27 [17%]). Known females (78) out-numbered known males (66), and never-smokers (45)
represented 36% of those with known smoking status. We subjected available samples to AIM analysis
to define the relative contributions of European, African American, and Indigenous American ancestries
in the cohort and in each individual patient. Overall, the cohort was primarily European (67%), followed
by Indigenous American (21%), and then African ancestry (12%). African ancestry was enriched in the
Puerto Rican sub-cohort, and Indigenous American ancestry was enriched in the group from Perú.
Table 1.1 Demographics of the Cohorts, Combined and Individual Results
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Demographic

Total Patients (N =
163)
No.

%

120

74

27
16

Sex
Male
Female
Unknown
Smoking
Ever
Never
Unknown

Histology
Adenocarcinoma
Squamous cell
carcinoma
Other*

Moffitt Cohort
93)

Perú
Cohort
(N = 24)

PR Cohort (N=
46)

%

No.

%

No.

%

65

70

31

67

24

100

17
10

15
13

16
14

12
3

26
7

0
0

0
0

66
78
19

46
54
NA

35
58
0

38
62
NA

20
12
14

63
38
NA

11
8
5

58
42
NA

80
45
38

64
36
NA

60
31
2

66
34
NA

17
4
25

81
19
NA

3
10
11

23
77
NA

Ancestry
% European
% African
% Indigenous
American

No.

(N =

67
12

79
10

64
22

63
6

21

11

14

31

*The Moffitt cohort includes 7 carcinoids; 3 non-small cell lung carcinomas, not otherwise specified; 2
large cell carcinomas; and 1 adenosquamous carcinoma. The Puerto Rico (PR) cohort contains 3
carcinomas, not otherwise specified, and 1 non-small cell lung carcinomas, not otherwise specified.
NA, not available

Prevalence of Somatic Mutations
Figure 1.1A presents the mutation frequency in the four most common drivers in lung adenocarcinoma
in NHWs. Within the adenocarcinoma histology, 37 (31%) had one or more EGFR variants and 17 (14%)
had KRAS variants. This analysis also showed a trend toward reduced rates in STK11 mutations
(p=0.065). The mutation rate of TP53 was indistinguishable (p=0.717) between H/Ls (49%) and NHWs
(46%).
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The relation between driver mutations and patient characteristics was also explored. Figure 1.1B
presents the mutation rates of EGFR, KRAS, STK11, and TP53 in male and female patients in each group.
Notably the rate of EGFR mutations was nearly 50% in Hispanic females. Mutations in KRAS and STK11
were reduced in Hispanic females and to a lesser extent in Hispanic males. The rate of TP53 mutations
was similar between male and female patients. Figure 1.1C presents a comparison between ever and
never-smokers among H/L and NHW patients. Mutation rates in KRAS and STK11 were much higher in
smokers for both H/L and NHW cohorts. In fact, no STK11 mutations were observed in the 45 H/L neversmokers. In NHWs, EGFR mutations were four times more common in never-smokers. In the H/L cohort,
this effect was much smaller. Mutations in TP53 were not strongly associated with smoking in either
cohort. Finally, mutations were examined as a function of smoking by sex. Although the numbers are
too small for statistical significance, Figure 1.1D reveals that EGFR mutations in males in the H/L cohort
were reduced in smokers, but there was no difference detected in female smokers vs non-smokers. In
contrast, a similar analysis in NHWs (Figure 1.1E) shows a clear increase in EGFR mutations in both male
and female non-smokers.
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Figure 1.1 Mutational frequency of the Hispanic cohort with respect to gender and smoking
(A) Mutation rate comparison between 75 H/L lung adenocarcinomas and 748 NHW. Histograms of the
4 most common mutations in NHW adenocarcinomas as indicated as percent patients with any detected
variant. Number of mutants or number in cohort is indicated above histograms. All significantly different
rates are indicated by Fisher exact test p values: *p <0.05, **p <0.01, ***p <0.001 (B) Mutation rate
comparison between males/females and H/Ls/NHWs. Same analysis as in panel A, except H/Ls and
NHWs were divided into male and females. (C) Mutation rate comparison between H/L (and NHW) ever
and never-smokers. Although statistically insignificant, trend suggests that EGFR mutations are seen
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more commonly in non-smokers, whereas KRAS and STK11 are more frequently mutated in smokers.
(D) Mutation rate comparison between H/L males/females and ever/never-smokers. Although
statistically insignificant, trend suggests that EGFR mutations are seen more commonly in non-smokers,
whereas KRASand STK11 are more frequently mutated in smokers. (E) Mutation rate comparison
between NHW males/females and ever/never-smokers.
EGFR mutations are associated with Indigenous American ancestry
In general, H/L individuals are characterized by a wide mixture of ancestries. Therefore, to explore the
role that ancestry may play in mutation frequency in the H/L cohort, the Ward linkage method was used
to separate the cohort into three ancestral clusters (Figure 1.2A). The mutation frequency of various
genes was then compared between the three clusters. Figure 1.2B reveals that EGFR mutations were
more common in the Indigenous America cluster but appear identical in the European and African
clusters. In contrast, TP53 mutations were much less common in the Indigenous American cluster,
whereas the frequency of TP53 mutations appeared identical in European and African clusters. KRAS
mutations were shown to be rare in the African cluster, and STK11 mutations were rare in both the
African and Indigenous American clusters, relative to the European cluster.
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Figure 1.2 Mutational rate comparison by ancestry
(A) The Ward linkage method and Euclidean distance metric were used cluster H/L patients by ancestry.
The clusters were classified as follows: 1) Indigenous American (green cluster), 2) African (red and left
blue cluster), 3) European (right blue cluster). (B) Mutation rate comparison between 3 ancestral
clusters. Mutation rates of 4 common drivers within the 3 ancestral clusters reveal a statistically
significant difference between TP53 mutations between Indigenous American and European (p=0.0087)
and Indigenous American and African ancestral clusters (p=0.011). The same comparison for EGFR has
a p value of 0.058 and 0.072, respectively.

23

Discussion
In previous reports, EGFR exhibited a higher rate of mutation and KRAS was suggested to have a lower
mutation rate in H/L patients compared with NHW patients.[104, 105, 111, 115] The data presented
here confirm these observations overall. Among the 120 H/L adenocarcinomas that we analyzed, 37
(31%) had EGFR mutations, compared with 17% in our TCC NHW cohort, and 17 H/L patients (14%) had
KRAS mutations. In a published NHW cohort, 11% of lung adenocarcinomas had EGFR mutations and
35% had KRAS mutations.[116] In addition, our data suggest that the elevation in EGFR mutations within
our H/L cohort is driven by females, with 48% having EGFR mutations (Figure 1.1B). Our data also
suggest altered mutation rates for other genes commonly mutated in NSCLC. Among adenocarcinoma
patients, the frequency of KRAS and STK11 mutations were reduced in H/L patients relative to NHW
patients.
Smoking is the primary driver of mutations in lung cancer. The overall percentage of non-smokers in the
H/L cohort was 36%. In comparison, a NHW cohort showed 9% non-smokers[116] and The Cancer
Genome Atlas lung adenocarcinoma cohort showed 7% non-smokers. Nonetheless, H/L individuals
appear to have a similar pattern as observed in NHWs for STK11 and KRAS in that mutations in both
genes increases with smoking in both groups (Figure 1.1C). Unlike NHWs, mutations in TP53 occurred
with nearly equal frequency in both smoking groups in the H/L cohort and the inverse correlation
between smoking and EGFR mutations was dampened in H/L patients. These results suggest that
smoking status was not the primary factor explaining the high rate of EGFR mutations in H/L patients.
The observation that KRAS and STK11 mutations are elevated in H/L smokers addresses the objection
that H/L ever-smokers are lighter smokers than NHW individuals. There may be differences in how
smoking influences the mutations observed in men versus women (Figure 1.1D-E). However, drawing
this conclusion firmly will require a larger dataset.
Finally, the role that ancestry might play in this cohort was examined by clustering patients into
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ancestral groups based on AIM analyses (Figure 1.2A). Whereas the analysis is only statistically
significant for the TP53 mutations, the data (Figure 1.2B) suggest that, relative to European ancestry,
Indigenous American ancestry correlates with low rates of TP53 and STK11 mutations and high rates of
EGFR mutations and African ancestry correlates to low rates of KRAS mutations. At this point, our
dataset is too small to make claims with respect other mutations that are even less common than these
four.
There are a few notable study limitations worth addressing. One of the most significant was the lack of
matched normal samples for each of the sequenced tumors. Likewise, we utilized various sources of
tissue and various sequencing technologies than should considered interpreting these data. Other
limitations include incomplete clinical data for several samples in our cohort that affected our ability to
determine statistical significance and lack of age, tumor stage and outcome data. Future studies will be
necessary to provide statistical power for additional comparisons. Nonetheless, this study is the first
addressing the lack of comprehensive genomic data in H/L lung cancer patients. The data suggest that
EGFR mutations in H/L lung adenocarcinoma patients are associated with their Indigenous American
ancestry.
Materials and Methods
Patients and Tissues
Three tissue sources contributed to this study (Table 1.1). Patient sex, smoking status, and tumor
histology were collected from patient medical records, as available. Patient age, tumor stage and
outcome were not available for enough of the patients for analysis. DNA sequencing and ancestry
analysis were performed on as many samples as possible; however, DNA was limiting in some cases.
Statistical comparisons were made on the largest subgroups possible, as indicated within each Figure or
Table. Tissue samples designated “Moffitt” were acquired from patients diagnosed primarily with NSCLC
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who consented to Moffitt Cancer Center’s Total Cancer CareTM (TCC) program between April 2006 and
August 2010. The University of South Florida (Protocols 00001222 and 00011723) Institutional Review
Board approved this study. Tissue samples designated “Puerto Rico” were acquired through the Puerto
Rico Bio-Bank. The Ponce Health Sciences University (Protocol 080121-IF) Institutional Review Board
approved this study. Tissue samples designated “Perú” were from untreated patients diagnosed with
lung adenocarcinoma who had surgery during the years 2013- 2014 in Lima, Perú, where institutional
approval was obtained locally for the collection of tumor blocks and clinical data.
DNA isolation
TCCTM-provided DNAs were extracted from fresh-frozen macro-dissected tumor tissues using Qiagen
DNeasy Blood & Tissue Kits according to the methods and consent protocols, previously described.[117]
DNA samples acquired through the Puerto Rico BioBank (PRBB) originated from lung biopsies in the
form of fine-needle aspiration collected in PAXgene Tissue Containers (Qiagen) or were from archived
tissue blocks. Samples from Perú were all from archived tissue blocks. Candidate tissue blocks were cut,
H&E-stained, and reviewed by the tissue procurement core pathologist to verify the diagnosis, histology,
and the amount of tumor present. Tumor margins were marked and each tumor specimen was excised
in Moffitt’s Tissue Core Facility. DNA quantity and quality were assessed using a Qubit and Tape Station,
respectively.
DNA sequencing
Sequencing information across exons of 1,321 genes for an initial 28 H/Ls samples was obtained via our
TCCTM institutional sequencing protocol.[117] Subsequently, another 76 samples were subjected to a
targeted Agilent panel matching the original 1321 genes of the TCCTM protocol. Another 11 samples
were subjected to an Illumina whole-exome sequencing panel. The processed sequencing reads were
analyzed on Moffitt’s cluster. Alignment and refinement was performed using BWA [118] and PICARD
(http://picard.sourceforge.net/) against reference hs37d5 and variant calling was done using GATK
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[119]through a BASH pipeline. The VCF file was annotated with ANNOVAR [120]and read and exported
using Varsifter 1.8[121]. Heterozygous or homozygous variants were exported only if they resulted in a
change in protein sequence. Synonymous and intronic mutations were excluded from analysis.
Additionally, since matching normal DNA samples were not available for many of the tumor samples, 25
unmatched normal samples from healthy Puerto Rican blood donors were sequenced and used to filter
the sequenced tumors. Any mutation occurring in the normal samples was removed. Quality filters
were applied and any variant call with a VSQR Tranche score from 99.90-100.00 was removed. To
further account for unmatched normal samples and eliminate false positive mutation calls the Broad
Institute EXAC database of SNP’s was downloaded. The EXAC database provides variant call frequency
by global population frequency (AF_GLOBAL) and maximum frequency in any ethnic subpopulation
(AF_POPMAX). Any variant call from our cohort that exceeded a 1% AF_GLOBAL or AF_POPMAX
frequency was removed. Finally, to account for batch effects of multiple sequencing types, identical
nucleotide variants that were associated with a single sequencing run and at a frequency greater than
that of the most common canonical mutation were excluded.
Global ancestry estimations
A set of 106 single nucleotide polymorphisms (SNPs) that discriminate Indigenous American, African,
and European ancestry was used to estimate the proportion of genetic ancestry. The SNPs were chosen
to maximize information for more than one ancestral population pairing, with a large difference in allele
frequency between ancestral populations. They are widely spaced throughout the genome and have a
well-balanced distribution across all 22 autosomal chromosomes. Genotyping was performed using a
multiplex PCR coupled with single base extension methodology with allele calls using a Sequenom
analyzer. The AIMs panel and reference populations have been described previously.[122] For each
sample, genetic ancestry was estimated using ADMIXTURE[123].
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Chapter 2: Immune suppression in STK11 loss of function lung adenocarcinoma is associated with noncanonical polyamine metabolism

Abstract
Purpose: STK11 (LKB1) mutations are common in lung adenocarcinoma. Recent studies demonstrate
that immunotherapies that block programmed cell death 1 (PD-1) function are very unlikely to benefit
patients with loss of STK11. We sought to identify targetable STK11-mediated metabolic pathways that
account for the lack of immune response.
Experimental Design: We utilized two previously described cohorts, TCGA and our own MLOS cohort,
representing approximately 1,000 lung adenocarcinoma patients, with available mutation, gene
expression and protein expression data, to identify metabolic pathways strongly associated with STK11
loss. We then subjected 126 tumors from our MLOS cohort to liquid chromatography-mass
spectrometry (LC-MS) to validate our predictions.
Results: Multiple gene-set enrichment analyses reveal patient tumors with predicted loss of STK11
upregulate amino acid catabolism, the urea cycle, and polyamine synthesis. ODC1 (ornithine
decarboxylase 1), the rate limiting step in polyamine biosynthesis, was identified as one of the strongest
genes associated with STK11 loss. ODC1 over expression in STK11 loss tumors was unique to human
samples and not significantly associated with STK11 loss in commonly-used cell line, mouse, or patientderived xenograft models. Untargeted LS-MS metabolomics validate the predictions based on
gene/protein expression, demonstrating that tumors with loss of STK11 function have increased
production of putrescine, gamma-aminobutyric acid (GABA), and pyridoxal with decreases in ornithine
and histamine.
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Conclusion: These data suggest a non-canonical and neuroendocrine-like utilization of putrescine for
GABA production, leading in turn to immune suppression. We predict that inhibition of this ODC1driven pathway could restore immunotherapeutic efficacy in an otherwise unresponsive cohort.
Introduction
In the current age of cancer therapeutics, immunotherapy has given us significant strides towards
increased progression free survival and even permanent remission in a small percentage of patients.
Some of the best responses to immunotherapy have been seen in subsets of immunogenic cancers such
as melanoma and lung cancer. However, despite successful treatments, the response rate rarely
exceeds 25% [36, 37]. Prediction of the patients who will benefit from immunotherapy through clinical
biomarkers is one hurdle to overcome. Perhaps the most difficult challenge is unraveling the
mechanisms underlying immunocompromised non-responders [35, 38]. Increased understanding of
these adaptations will pave the way for better personalized combination therapy.
STK11, also known as LKB1, is a well-established mediator of stress and has been shown to be mutated
in roughly 18% of all lung adenocarcinomas (LUAD), the most incident histology of all lung cancer [10].
Patients harboring tumors deficient in STK11 signaling have been shown to have a reduction in the
infiltration of cytotoxic T-cells and respond poorly to anti PD-L1 therapy [47-49, 52, 53]. Functionally,
STK11 lies downstream of PKC (protein kinase C) and upstream of AMPK and is responsible for
phosphorylating ~14 kinases in response to alterations in cellular energy homeostasis [40, 124]. In times
of metabolic stress, or a high cAMP/ATP ratio, STK11 phosphorylates AMPK resulting in activation of
catabolic pathways over anabolic ones. This molecular switch has been displayed by the role of STK11
on mTOR inhibition and autophagy induction. Changes in the functional status of STK11 have been
linked to alterations of methylation, metabolism, cellular polarity, differentiation, and apoptosis [41, 42,
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44, 46, 67, 125]. While much is known about STK11’s role in metabolism, it is unclear at this point, what
role altered metabolism plays in tumor suppression, particularly in regard to immune evasion.
In this study, we use gene and protein expression data on nearly 1000 lung adenocarcinoma patients to
identify potential metabolic alterations associated with STK11 loss of function that could explain its
immune suppressed microenvironment. These analyses identified ornithine decarboxylase 1, which
converts ornithine to putrescine and is the first step in polyamine biosynthesis, as one of the most
upregulated genes in STK11 loss tumors. Polyamines are found in nearly every life form and are
thought to be one of the most intricately regulated aspects of biology. They are essential for cell
proliferation and are known to bind DNA and minimally regulate both transcription and translation [73].
Furthermore, polyamine upregulation has been shown to cause immunosuppression and inhibition of
their synthesis has been shown to alleviate this phenotype [70, 71, 79, 80]. Interestingly, this
upregulation did not occur in cell lines, mouse or patient-derived xenograft models, limiting our ability
to validate upregulation of polyamines in STK11-loss tumors experimentally. To circumvent this
limitation, we obtained fresh frozen tissue from 126 lung adenocarcinoma patients and subjected them
to liquid-chromatography-mass spectrometry to measure the levels of polyamines and other
metabolites in tumors. As predicted, we find that tumors with loss of STK11 function have increased
levels of putrescine and decreased levels of its precursor ornithine.
Results
Gene expression patterns of STK11 mutants by DNA-sequencing
According to TCGA’s pan-cancer study, DNA mutations of STK11 are most commonly found in large cell
neuroendocrine lung tumors at a rate of 33% followed by LUADs at 18% (Figure 2.1). Previously, we and
others have reported gene expression-based classifiers that can distinguish STK11 mutated tumors from
those with wildtype STK11 [53, 126-128]. In the present work, we extend this gene expression analysis
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to in vivo data. First, we sought to characterize similarities between RNA expression changes in two well
annotated LUAD datasets: TCGA (N=515) and Moffitt’s MLOS (N=442) (Figure 2.2A). Each of these
datasets contains both DNA sequencing and RNA expression data on the majority of patients. The initial
test involved determining which patients had a sequenced STK11 mutation in each dataset and
comparing them to their (wildtype) un-mutated counterpart. TCGA contained (76) mutant patients by
DNA-sequencing and (409) confirmed wildtype patients while MLOS contained 68 and 374 respectively
(Table 2.1). In each study only the genes changing by at least +/- 1.5 Fold and with a Bonferroni
corrected p-value of < 1e-10 by student’s t-test was further considered. TCGA had 64 genes that
surpassed these criteria and MLOS contained 71 genes. Taken together, 29 genes overlapped and were
used for gene set enrichment (Figure 2.2B and Table 2.2). Upon closer examination, STK11 mutant
patients’ tumors show a significant up-regulation of several solute transporters (SLC7A2, SLC14A2, and
SLC16A4) (Table 2.2). SLC7A2 is known to be responsible for the membrane transport of cationic amino
acids arginine, lysine, and ornithine. SLC14A2 is surprisingly responsible for the transport of urea and is
the end result of nitrogen detoxification. SLC16A14 (MCT14) is part of the monocarboxylate transporter
family and has been shown to be highly abundant in both the kidney and central nervous system. This
family of transporters is known for their transfer of carboxylic acids. In addition to these family of
transporters we also observe a consistent upregulation of CPS1 (Carbamoyl-phosphate synthase 1),
which has previous been associated with pathway disruption of STK11 [61, 62], and ODC1 (ornithine
decarboxylase), which has not been previously associated with STK11. Taken together, these genes
cooperate in the regulation of the urea cycle, with CPS1 being responsible for the initial incorporation
and removal of both ammonia and bicarbonate and ODC1 catalyzing the rate limiting step of polyamine
biosynthesis from ornithine, another urea cycle intermediate. Genes regulating transport suggest that
these cells are increasing their flux of the transport of ornithine, arginine, and urea which further point
to the enrichment of this liver-associated biological pathway. Using the 29 genes in gene set enrichment
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analyses (Genemania and mSigDB’s Hallmark datasets described in the Supplementary Materials)
support the conclusion that the polyamine pathway, highlighted in Figure 2.2C, is dramatically altered in
STK11 mutant tumors.

Table 2.1 – STK11 mutant statistics and signature prediction
MLOS

WT Sig (N, (%))

Mutant Sig (N, (%))

Total (N, (%))

WT DNA

297 (67.2)

77 (17.4)

374 (84.6)

Mutant DNA

0 (0)

68 (15.4)

68 (15.4)

Total

297 (67.2)

145 (32.8)

442 (100)

TCGA

WT Sig (N, (%))

Mutant Sig (N, (%))

Total (N, (%))

WT DNA

314 (61.0)

95 (18.4)

409 (79.4)

Mutant DNA

4 (0.80)

72 (14.0)

76 (14.8)

Unknown

19 (3.7)

11 (2.1)

30 (5.8)

Total

337 (65.5)

178 (34.5)

515 (100)
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Figure 2.1 STK11 mutations most frequently occur in large cell neuroendocrine carcinoma and lung
adenocarcinoma
Cbioportal bargraph representing the detectable STK11 mutation frequency amongst all cancer types,
with the most frequent histology being large cell neuroendocrine cancers followed by lung
adenocarcinoma.
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Figure 2.2 STK11 mutations result in transcriptional changes related to amino acid metabolism
(a) Introduction of the cohorts we will be using for the duration of the study. Moffitt’s Lung Overall
Survival (MLOS) cohort contains 442 patients, with 150 of those patients on a tumor microarray for IHC
staining, and 126 of those patients were analyzed using LC-MS untargeted metabolomics. TCGA contains
515 LuAD tumor samples with 360 of those patients having reverse phase protein array (RPPA) data.
These two cohorts will be used in parallel to confirm our hypotheses. (b) Venn-Diagram displaying the
overlap of genes changing as a result of STK11 DNA level mutations in both cohorts. Using a Bonferroni
corrected p-value of < 1e-10 and a linear fold change of +/- 1.5, 29 genes were found to be significantly
altered in both studies. (c) Gene set enrichment utilizing both Genemania and mSigDB’s Hallmark
datasets suggest disruption of the canonical polyamine metabolism pathway highlighted here.
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Table 2.2 - STK11 DNA mutation related gene expression changes
Gene

MLOS BF pvalue

MLOS
FC

MLOS
RANK

TCGA BF pvalue

TCGA
FC

TCGA
RANK

Average
Rank

Average
FC

LINC00473

3.3E-32

6.70

1

1.56E-29

26.96

1

1.0

16.83

SLC16A14

1.19E-31

6.06

2

7.95E-24

6.07

3

2.5

6.06

PDE4D

4.63E-20

2.73

6

2.8E-26

3.74

2

4.0

3.23

ODC1

1.42E-25

2.62

3

1.49E-20

3.59

7

5.0

3.10

INHA

1.91E-19

4.34

7

6.59E-23

14.46

4

5.5

9.40

SLC7A2

1.27E-22

4.50

4

1.92E-20

7.01

8

6.0

5.75

CPS1

7.06E-19

4.88

9

5.68E-21

28.80

6

7.5

16.84

SLC14A2

1.85E-22

4.34

5

3.52E-19

12.72

10

7.5

8.53

DUSP4

4.21E-18

2.94

10

3.71E-18

4.10

11

10.5

3.52

IRS2

5.08E-16

2.02

16

7.69E-23

3.29

5

10.5

2.65

FXYD4

1.3E-17

2.41

11

2.22E-16

7.86

15

13.0

5.13

GLTPD2

2.18E-15

2.21

17

3.96E-18

7.10

12

14.5

4.65

INSL4

3.22E-17

5.71

14

3.01E-14

9.25

18

16.0

7.48

BAG1

4.11E-15

1.57

20

3.22E-17

1.89

13

16.5

1.73

FGL1

2.82E-15

6.73

18

5.32E-15

17.50

16

17.0

12.11

HAL

6.91E-15

3.79

21

8.55E-17

6.72

14

17.5

5.26

PPARGC1A

1.86E-16

3.14

15

3.39E-14

5.17

20

17.5

4.16

KSR1

1.98E-19

1.92

8

2.97E-11

2.12

29

18.5

2.02

KCNU1

5.36E-11

2.09

29

2.44E-19

4.56

9

19.0

3.32

GALNTL6

1.85E-17

4.49

12

1.21E-11

3.36

28

20.0

3.93

EYS

2.01E-17

2.19

13

7.95E-12

3.00

27

20.0

2.60

CALCA

3.44E-15

7.31

19

7.95E-13

20.24

24

21.5

13.77

TACC2

2.25E-13

2.18

24

3.18E-14

2.56

19

21.5

2.37

ADSSL1

2.65E-11

2.06

28

1.96E-14

2.68

17

22.5

2.37

FURIN

4.85E-14

1.65

22

3.08E-13

2.33

23

22.5

1.99

AIM1

1.21E-13

-2.08

23

2.5E-13

-2.54

22

22.5

-2.31

BMP6

5.95E-13

2.70

25

1.97E-13

3.82

21

23.0

3.26

PDE3A

2.26E-11

2.47

27

8.53E-13

3.92

25

26.0

3.20

VPS37A

1.2E-12

1.91

26

3.65E-12

1.61

26

26.0

1.76
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Expansion and classification of patients with STK11 loss
We hypothesized that DNA sequencing would only reveal a portion of patients with the same phenotype
of STK11 mediated pathway disruption with chromosomal loss of 19p13, methylation of the STK11
allele, or alterations in up or downstream pathways accounting for STK11 loss-of-function without
mutation. When using our 29-gene signature as a classifier for STK11 status and utilizing principal
component analysis (PCA) in LUAD patients in both TCGA and the MLOS we discovered that nearly twice
as many patients have gene expression patterns imitating mutations in STK11 based on the 1st principal
component (PC1) (Figure 2.3 A-B). Thus, we derived a signature score based on PC1 coefficients from
TCGA and MLOS cohorts (Supplementary Methods and Supplementary Table 2.3) to reclassify patient
STK11 loss with a signature score greater than 0 were classified as mutant and less than 0 were classified
as wildtype. Upon reclassification of patients into either mutant-like or wildtype, we analyzed these
new cohorts for gene expression changes (Figure 2.3 C-D). The volcano plot of genes changing as a result
of STK11 loss of function reveal far more upregulated genes than downregulated ones. With many
patient tumors harboring expression patterns imitating that of an STK11 mutation and representing
false negatives for detection of an STK11 mutation that were classified into our initial wildtype cohort,
our first analysis was statistically weakened. While many of the hallmarks of STK11 pathway disruption
remained constant in this new analysis, many others now surpassed our threshold of statistical
significance (Supplemental File 1). By keeping our threshold of a fold change of +/- 1.5 consistent, we
increased our Bonferroni corrected p-value to only include genes with a value of less than 1e-15. Even
with this increase in stringency we observed statistically relevant changes in 451 genes in TCGA and 165
genes in the MLOS, with 137 genes overlapping between both of these datasets (Figure 2.4A). All genes
upon re-classification have much greater statistical significance and fold changes. It is worth noting that
the long non-coding RNA annotated as both LINC00473 and C6ORF176 are consistently the best marker
of STK11 loss of function in both studies [129].
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Table 2.3 - STK11 signature gene PCA coefficients
Gene
CPS1
CALCA
FGL1
LINC00473
INSL4
INHA
SLC14A2
SLC7A2
SLC16A14
HAL
PPARGC1A
DUSP4
FXYD4
BMP6
GLTPD2
GALNTL6
KCNU1
PDE3A
PDE4D
ODC1
IRS2
EYS
TACC2
FURIN
ADSSL1
KSR1
VPS37A
BAG1
AIM1

TCGA PC1
0.3739
0.3737
0.3470
0.3284
0.2224
0.2620
0.2500
0.2101
0.1811
0.1917
0.1820
0.1519
0.2094
0.1579
0.1768
0.1103
0.1529
0.1303
0.1169
0.1222
0.1113
0.1092
0.0889
0.0940
0.0743
0.0771
0.0519
0.0488
-0.1045

MLOS PC1
0.2756
0.2567
0.2375
0.2099
0.1950
0.1553
0.1491
0.1646
0.1798
0.1554
0.1337
0.1396
0.0820
0.1235
0.0789
0.1416
0.0829
0.1033
0.1016
0.0959
0.0759
0.0681
0.0770
0.0564
0.0759
0.0697
0.0706
0.0431
-0.0760

Average PC1
0.3248
0.3152
0.2922
0.2692
0.2087
0.2087
0.1995
0.1874
0.1804
0.1736
0.1579
0.1457
0.1457
0.1407
0.1279
0.1259
0.1179
0.1168
0.1092
0.1090
0.0936
0.0886
0.0829
0.0752
0.0751
0.0734
0.0612
0.0459
-0.0902

Principal component 1 from both MLOS and TCGA using the 29 consensus genes.
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Figure 2.3 Generation of a gene expression signature to predict STK11 loss of function in patients
(a-b) Principal component analysis using the 29 genes from Figure 2.1 in the MLOS (a) and TCGA (b)
cohorts. Patients with detected DNA mutations in STK11 are indicated in blue and wildtype in red. (c-d)
Volcano plot of genes changing between patients with a signature score > 0 (mutant) or < 0 (wildtype) in
MLOS (c) and TCGA (d).
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Predicted STK11 loss is associated with changes in nitrogen metabolism and the immune
microenvironment
Following expansion of the STK11 pathway disruption signature, GSEA was re-run on the 137 genes.
This time, MSigDB’s Hallmarks revealed enrichment in Inflammatory Response (FDR = 8.77e-13),
Interferon Gamma Response (FDR = 8.77e-13), as well as Interferon Alpha Response (FDR = 1.58e-8).
This result is interesting because it supports the observation that disruption of the STK11 signaling
pathway with respect to our signature involves an alteration of the inflammatory and immune response
of the tumor microenvironment (Figure 2.4B). It is our hypothesis that these changes in the immune
landscape are influenced by metabolic alterations in the microenvironment resultant of an altered stress
response. Genemania’s enrichment was in support of this altered immune reactivity with the top
biological processes being response to virus (FDR = 1.1e-14) and response to type I interferon
(FDR=9.17e-14) (Supplemental File 2-3). Using our own K-means enrichment algorithm described in
Materials and Methods, we discovered that gene sets pertaining to amino acid metabolism, polyamine
metabolism, and the urea cycle were most significantly useful in distinguishing predicted STK11 mutant
from wildtype tumors (Figure 2.4C). Altogether, these data suggest that upregulation of amino acid
catabolism, nitrogen processing through the urea cycle, and polyamine metabolism could be influencing
the immune silent microenvironment seen in patients with STK11 mediated pathway disruption.

Additionally, we thought it would be interesting to take our STK11 signature and apply it to each cancer
type in TCGA’s pan-cancer study. Patients with a high relative STK11 pathway disruption score exist in
lung adenocarcinoma as shown, but also in cervical cancer, kidney papillary and clear cell carcinoma,
breast cancer, lung squamous cell carcinoma, stomach adenocarcinoma, and liver hepatocellular
carcinoma. Liver has the highest overall signature for STK11 loss than any other cancer by a good
margin (Figure 2.4D). The liver is a uniquely capable of responding uniquely in times of energy
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deprivation and utilizing amino acids and fats for energy [86]. It is also the main site of the urea cycle,
responsible for processing most of the body’s excess nitrogen and excreting it in the form of urea. This
observation fits the hallmark of STK11 loss very well and helps support this novel role of amino acid
degradation.
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Figure 2.4 Gene set enrichment and pathway prediction of STK11 loss
(a) Venn-Diagram displaying genes changing by a Bonferroni corrected p-value of < 1e-15 and a linear
fold change of +/- 1.5. In both TCGA and MLOS there are now 137 genes that overlap. (b) MsigDB’s
Hallmark geneset overlap between the 137 genes seen in (a). (c) A novel method of gene set enrichment
using unsupervised K-means clustering of genesets between patients with predicted STK11 loss of
function. (d) Application of the STK11 signature to TCGA’s pan-cancer dataset by cancer type.

ODC1 elevation is specific to patient tumors with STK11 loss
We sought to determine whether elevation of ODC1 could be studied outside the context of patient
tumors with predicted STK11 loss. We applied the patient tumor derived STK11 signature to the
following datasets: cell line datasets (GSE36133 and GSE68950) (Figure 2.5A), patient derived lung
xenografts (PDX) (GSE78806) (Figure 2.5C), and patient datasets (MLOS and TCGA) (Figure 2.5D).
Additionally, we characterized the expression of ODC1 in Cre mouse studies of primary tumors between
KRAS and KRAS/STK11 mice (Figure 2.5B). Similar to our patient datasets, samples with a signature
score higher than 0 were considered mutant-like and less than 0 wildtype. To our surprise, cell line
datasets (p = 0.443 and 0.843), mouse models (p = 0.753), and PDX models (p=0.165) of STK11 loss
showed no significant change in ODC1 expression despite ODC1 being a significant driver of the STK11
signature. These data suggest the limitations of studying this biological mechanism outside of the
patient setting with further studies being required to elucidate its patient specific conservation.
Patients with STK11 loss have elevated levels of ODC1 protein
We have shown that by gene expression ODC1 is significantly elevated in patients with predicted STK11
loss of function (MLOS p = 1.9e-54 and TCGA p = 1.05e-56) (Figure 2.5D). In order to validate whether
or not tumors with STK11 mutations have a detectably higher level of ODC1 activity than WT tumors, we
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ran a western blot on protein extracts from a dozen patient tumors from the MLOS cohort. This western
blot was done on patients with detectable DNA level STK11 mutations and validates that there is a
strong association between the levels of mRNA and functional protein (Figure 2.5E). Further, we then
compared ODC1 gene expression and STK11 loss signature score in these patients. There is a clear
correlative relationship between the STK11 loss signature, ODC1 protein, and ODC1 gene expression.
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Figure 2.5 ODC1 elevation is specific to patient tumors
(a) Boxplot of predicted STK11 mutant (CCLE n=24, GSE68950 n = 14) and WT(CCLE n=50, GSE68950 n =
24) cells for ODC1. (b) Boxplot of ODC1 expression in primary lung tumors from KRAS (n=9) and
STK11/KRAS (n=9) transgenic mice in GSE21581. (c) Boxplot of ODC1 expression in human patient
derived xenograft models from GSE78806 based on predicted STK11 status. (d) Boxplot of ODC1
expression between patients with predicted STK11 loss of function and wildtype in MLOS (left) and
TCGA (right). (e) Western blot on patient samples based on DNA level detected mutations.
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STK11 loss is associated with a lack of immune infiltration
One pattern observed in the subset of patients with STK11 pathway disruption is the inverse relationship
with immune components and inflammation [53, 65]. We suspect that the lack of immune response is
supported by the lack of tumor PD-L1 expression because it suggests that the immune evasion is
through a mechanism independent of PDL-L1 activity. Several key elements of the immune response
are notably reduced in STK11 mutant patients such as co-stimulatory molecules CD40 and CD80, antigen
presentation in the form of MHC class I and II, immuno-inhibitory ligands PD-L1 (CD274), inflammasome
complex formation through AIM1, and chemotactic recruitment of cytotoxic cells in the form of CX3CL1
[130-133] (Supplemental File 1).

In order to further validate this observation in coordination with our gene set enrichment results we
compared PD-L1 abundance (CD274) on both the mRNA and protein level between mutant and wildtype
STK11 patients. Patients with an STK11 mutation have significantly lower amounts of PD-L1 mRNA
(p<1e-12) and protein (p=1.04e-6) (Figure 2.6E). We believe that this lack of PD-L1 expression is due to
the lack of T-cell infiltration and immune reactivity. In order to look more globally at the association
between inflammation and STK11 status, we clustered lung adenocarcinoma patients by MsigDBs gene
list for Interferon Signaling titled “REACTOME_INTERFERON_SIGNALING”, containing 159 gene symbols
validated for this pathway. We used these data as a surrogate marker of immune activation in all LUAD
patients. We used K-means clustering to separate both TCGA LUAD (n=515) and MLOS (n=442) into 3
distinct subpopulations (Interferon low, medium, and high) (Figure 2.6 A-B). Both TCGA and MLOS
clustered into similar distributions, with roughly 20% of samples falling into the Interferon Low subset
(Table 2.4). We used Fisher’s Exact test to analyze these populations for enrichments in DNA mutations
(Figure 2.6 A and C). In addition, we applied the STK11 signature to these clusters and there was a
significant difference between Interferon low and high populations in both TCGA (p=7.37e-33) and
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MLOS (p=4.06e-33). STK11 is the leading mutation accounting for the changes in interferon signaling
and is inversely related to Interferon levels between IFN_Low and IFN_High (p= 4.51E-12) in TCGA and
between IFN_Low and IFN_High (p= 4.29e-7) in MLOS. It is interesting that mutations in EGFR and TP53
both trend in the direction opposite of STK11 mutations. This outcome is likely due to both of these
mutations being mutually exclusive with STK11 suggesting preservation of the p16/TP53 signaling
pathway in patients with STK11 loss as similar seen in large cell neuroendocrine tumors [134]. However,
we suspect that EGFR is effecting interferon signaling through downstream kinase activity and TP53 is
increasing neo-antigen levels and that both likely contribute to the increase in inflammatory signaling.
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Figure 2.6 STK11 loss of function and polyamine metabolism is associated with lack of immune
infiltration
(a, c) K-means clustering was used on mSigDB’s Interferon Geneset (n=159 genes) to cluster patients
from MLOS (a top) and TCGA (c top) into 3 subsets of varying interferon response. Corresponding DNA
Mutation rate was calculated by Fishers Exact test between subsets (a, c bottom). (b, d) The STK11
signature was calculated in these three subsets in MLOS (b) and TCGA (d). (e) CD274 (PD-L1) expression
was determined in MLOS (far left) TCGA (far right) and paired with IHC data in MLOS and RPPA in TCGA.
(f, g) Pearson correlation coefficient was plotted between canonical immune markers (CD19, CD274,
IFNG, PDCD1, CD8A) and STK11 related biomarkers (ODC1,NKX2-1,KIT) in MLOS (f) and TCGA (g).
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Table 2.4 - Interferon gene-set K-means association with STK11 status
TCGA (N, (%))

STK11 Mutation %

MLOS (N, (%))

STK11 Mutation %

Low

100 (19.42)

35

87 (19.68)

36

Mid

212 (41.17)

17

172 (38.91)

13

High

203 (39.42)

3

183 (41.4)

9

ODC1 and the polyamine pathway is associated with immune suppression
Polyamines have been studied for decades and recent literature has shown the impact that polyamine
inhibition can have on reversing tumor-associated immune suppression [70, 71, 79, 80]. In order to
determine if there was a relationship between ODC1 activity and the loss of PD-1 and PD-L1 observed in
STK11 mutant patients we looked at the correlation between STK11 relevant genes and common
immune markers (Figure 2.6 F-G). In order to answer this question in the appropriate context, only
patients with predicted STK11 loss of function were used for the correlation, given that we have already
shown that STK11 loss of function itself is associated with a lack of immune infiltration. By gene
expression ODC1 has a strong inverse relationship to PD-1(PDCD1), CD8A, and PD-L1 (CD274) (Figure 2.6
F-G). While correlation does not prove causation, this result is consistent with the relevance of ODC1
biology to the observed decrease in both cytotoxic T-cell markers and tumor intrinsic immune
suppression in patients with loss of STK11.
Increased metabolite production of putrescine and GABA in patients with STK11 loss
Following our discovery of both elevated ODC1 in patient tumors and its inverse relationship to
inflammatory signaling, we sought to validate our hypothesis that this elevation was reshaping the
microenvironment and could potentially explain changes in immune surveillance. In order to accomplish
this, we subjected 126 patient samples of the TMA150 cohort to untargeted metabolite profiling using
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LC-MS and generated datasets containing over 6,200 features. Of these features, approximately 250
were identified by comparison to a library of metabolite standards. Using the STK11 signature in MLOS,
we looked for differential features and metabolites as a result of predicted STK11 loss of function. In
support of our hypothesis, putrescine was one of the most significantly elevated metabolites supporting
increased ODC1 activity (Figure 2.7A). To our surprise, rather than the canonical downstream
polyamines spermidine and spermine being elevated, we observed an increase in 4-aminobutanoate,
also known as gamma-aminobutyric acid (GABA) which had the strongest correlation to putrescine in
our study (Figure 2.7B). Additionally the acetylated counterparts of both putrescine and GABA were
almost equally enriched (Table 2.5). We also looked at the relationship of ODC1 to Putrescine and
noticed that there is a significant positive correlation (r = .30, p=.0008) (Figure 2.7C).
The strong relationship between Putrescine and GABA production in patients with predicted STK11 loss
of function highlights the observed increase in amino acid catabolism through the deamination of
putrescine. The increased level of vitamin B6 (pyridoxal) supports this observation. Pyridoxal is used as
a co-factor when amino acids are utilized for energy through deamination or transamination reactions,
in some cases both releasing ammonia and creating a carbon backbone. Evidence of this pathway is
seen by the increase in gene expression of alanine aminotransferase (GPT2), ornithine aminotransferase
(OAT), and histidine ammonia-lyase (HAL) (Supplemental File 1). Complementing these
aminotransferase reactions is the increase in urea transport through SLC14A2 and key enzymes of the
urea cycle, such as CPS1 and ODC1, suggesting the need to release an excess of ammonia. We
hypothesize that GABA could potentially be used as a TCA cycle intermediate through conversion to
succinate as succinic acid is part of the putrescine-GABA co-expression network. (Figure 2.7D).
We then used Mummichog (http://mummichog.org/index.html) to predict pathway and network
analysis from m/z values in our metabolomics data (Table 2.6). This software is capable of making
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multiple calls to indistinguishable m/z values, allowing for the statistical inference of metabolic
pathways based on enrichment. When comparing untargeted metabolites between STK11 mutant and
wildtype patients the most enriched pathway was arginine and proline metabolism (p=0.000945), both
of which are precursors for the synthesis of ornithine required for polyamine metabolism. Other
interesting pathways include fatty acid metabolism (p=0.001832) and the urea cycle (p=0.008426).
Combined data from the transcriptome, proteome, and metabolome all converge to highlight the
increase in amino acid catabolism, urea cycle, and polyamine metabolism in patients lacking functional
STK11.
Table 2.5 - Metabolites elevated in predicted STK11 mutants
Study Symbol
ETHYLMALONIC ACID(-)
4-ACETAMIDOBUTANOATE(-)
4-ACETAMIDOBUTANOATE(+)
PUTRESCINE(+)
4-AMINOBUTANOATE(+)
N-ACETYLPUTRESCINE(+)

P-Value
4.87E-08
3.13E-07
5.65E-07
6.90E-07
2.11E-06
3.33E-05

Fold Change
2.01
2.18
1.93
2.28
1.81
2.18

Table 2.6 - Enriched pathways in predicted STK11 mutants through use of Mummichog
Pathway
Overlap Size Pathway Size
Arginine and Proline Metabolism
19
35
Carnitine shuttle
13
21
Fatty acid activation
9
17
Lysine metabolism
12
27
Drug metabolism - other enzymes
8
16
Aspartate and asparagine metabolism
25
67
Tryptophan metabolism
23
62
Glycerophospholipid metabolism
17
44
Limonene and pinene degradation
4
6
Beta-Alanine metabolism
6
12
Vitamin B3 (nicotinate and nicotinamide) metabolism
9
21
De novo fatty acid biosynthesis
9
21
Valine, leucine and isoleucine degradation
12
31
Urea cycle/amino group metabolism
17
47
50

P-Value
0.000945
0.000959
0.001832
0.002657
0.002891
0.003461
0.004141
0.004313
0.004526
0.005374
0.00567
0.00567
0.007426
0.008426
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Figure 2.7 Putrescine and GABA are elevated in patients with STK11 loss of function.
(a) Volcano plot of average peak heights of annotated metabolites in STK11 mutants compared to
wildtype (left) and unannotated metabolites (right). (b) Correlation matrix displaying Pearson
correlation coefficient between metabolites significantly altered in STK11 mutants. (c) Plotted
correlation between ODC1 gene expression and linear peak height of Putrescine. (d) Schematic
representing the potential mechanism by which STK11 mutants alter the GABA-Putrescine metabolic
pathway.

Discussion
Here we provide an in vivo signature for functional loss of STK11, useful in the classification of patients.
We believe that the evidence provided has shown that patients with loss of STK11 have elevated levels
of ODC1 both gene and protein leading to increased production of putrescine, the product of ODC1
activity. It has been established that ODC1 is a target of MYC [58-60, 135]and previous literature has
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shown that STK11 is a repressor of MYC activity. We believe that loss of STK11 takes the brakes off of
MYC and could be the mechanism behind the observed increase in polyamine synthesis. Given the
immunosuppressive nature of both MYC-driven cancers and polyamine synthesis, we believe that
targeted inhibition of this pathway in combination with anti-PD-1/PD-L1 immunotherapy would increase
survival in patients with loss of STK11 function. ODC1 is targetable through the FDA approved drug
DFMO (Difluromethylornithine), which acts as an irreversible inhibitor of ODC1 [68, 77, 78, 136]. Until
now, DFMO has not been considered a treatment strategy for lung cancer, as it is most commonly
associated with MYC/MYCN driven diseases such as prostate cancer or neuroblastoma respectively [68,
78]. Taking the above mentioned associations into consideration, STK11 mutant tumors not only
overexpress the MYC target ODC1, but also inhibition of this pathway with DFMO could be used to
partially reverse the immunosuppressive characteristics as well as result in metabolic disruption and
growth arrest. Unique to this cell lineage however, polyamine synthesis appears to be shunted towards
GABA production rather than downstream polyamines spermidine and spermine. In support of this
observation, ornithine and urea transport is also transcriptionally upregulated in patients with loss of
STK11 function through genes SLC7A2 and SLC14A2 respectively.
Loss of STK11 greatly impacts cell lineage [137] and in a future publication we will discuss in further
detail the difficulty in studying changes in STK11 mediated metabolism outside the patient setting
(Figure 2.5) Very clearly, STK11 mutations are associated with both the neuroendocrine and
adenocarcinoma lineage; a majority of STK11 mutant lung adenocarcinomas mimic the large cell
neuroendocrine characteristics of co-occurring KRAS and KEAP1 mutations, MYCN amplification, and
expression of ASCL1 [134]. Therefore, these two cell types may share common genetic machinery that
sets the stage for a unique metabolic phenotype resulting from STK11 loss. Our data suggest that this
loss results in synthesis and accumulation of the neurotransmitter, GABA, and its precursor putrescine,
which fits the neuroendocrine cell fate [98, 99, 138]. Additionally, NKX2-1 positive type II pneumocytes,
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which give rise to lung adenocarcinoma, contain the enzymes required for this conversion [8, 9, 20].
Monoamine oxidase is required for the conversion of putrescine to GABA-aldehyde and ALDH3A2 is
required for the conversion of GABA-aldehyde to GABA, both of which correlate with ODC1, putrescine,
and GABA. We hypothesize that GABA might be acting to depolarize immune cells along with the other
immunosuppressive intermediates downstream of the polyamine pathway [91, 93, 96]. In addition, we
believe that GABA can also be used as an energy substrate of the TCA cycle through GABA’s conversion
to succinate through GABA-amino transferase, limited by the enzyme GABAT [100]. Notably, pyridoxal
(vitamin B6) is required as a co-factor for nearly every transamination or deamination reaction and even
for decarboxylation. The increase in pyridoxal seen in this subset of patients only further supports this
hypothesis. It is worth noting that the conversion of GABA to succinate bypasses two NAD+ to NADH
steps of the TCA cycle, isocitrate to alpha-ketoglutarate and alpha-ketoglutarate to succinate. This
observation could potentially guide us to metabolic vulnerabilities in STK11 deficient patients.
A difficulty of this study is that our pathway of interest has been shown to be one of the most intricately
regulated of all human pathways with transcriptional and translational half-lives in the range of 5-30
minutes [68, 69, 72, 75]. Additionally, ODC1 and polyamine metabolism does not appear to be
upregulated in any cell line database, syngeneic mouse model, or xenograft model as a result of STK11
loss. However, every patient dataset shows a significant upregulation. Given the specificity of ODC1
activity to patient tumors, this study could have captured metabolic alterations missed in other model
systems. We believe this patient specificity to be a result of cellular plasticity and differentiation due to
STK11 loss in cells grown outside their natural environment. A number of other studies have alluded to
STK11’s role in cell fate [30, 137]. Likely, various environmental stimuli and cell of origin greatly impact
this observation. When dealing with potent regulators of metabolism such as STK11, it is important to
study the cells in a similar metabolic environment that would be present in patients. Xenograft models
and tissue culture fail to recapitulate many variables that would be altered exclusively in the lung such
54

as: glucose, amino acids, fatty acids, immune cells, oxygen concentration, pH, paracrine signaling from
stromal tissue, and many more. While mouse models seem to be the answer to this question, gene
expression patterns are vastly different in murine and human tumors. We believe that since
neuroendocrine cells and type II pneumocytes constitute such a small fraction of lung cells that deleting
STK11 non-specifically in the lung results in a tumor of mixed histology with cell lineages pertinent to
lung adenocarcinoma making up far less than 10% of the tumor.
In conclusion, this paper puts forward a method by which patients with STK11 loss could be classified
through gene expression signature and selected for combination anti-PD-1/PD-L1 immunotherapy with
targeted inhibition of ODC1. Given that this cohort would not otherwise respond to immunotherapy,
the actionable and targeted inhibition of polyamine metabolism through DFMO as suggested from
previous studies would abrogate the immunosuppressive microenvironment and potentially restore
immunotherapy efficacy in this large subset of patients, greatly increasing patient survival and taking
one step further towards both personalized medicine and potential elimination of a deadly disease.
Materials and Methods
Acquisition of publicly available genomic and proteomic datasets
The TCGA LuAD dataset was downloaded from the Xena browser (https://xenabrowser.net/hub/) for
gene expression (RNAseq), protein expression (RPPA), and somatic mutation. MLOS (GSE72094) has
been previously described [53, 116, 126, 129, 139, 140].
Statistical analysis
Statistical analysis was performed using the Scipy python package and the function scipy.stats.ttest_ind
for p-value between gene arrays. Bonferroni correction was used by multiplying the p-value by the
number of genes in the study. Pearson correlation was calculated through the scipy.stats.pearsonr
function.
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Public gene-set enrichment software
Two publically available methods of gene-set enrichment were used in this study. Genemania
(http://genemania.org/) available as a web-based software was used on overlaps between TCGA and
MLOS by t-test for both the 29 and 137 length gene-sets. Similarly, Broad Institute’s Hallmark gene-sets
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) were used with a FDR cutoff of 0.05.
Pathway Schematics
Pathways were generated using the PathVisio software available here https://www.pathvisio.org [141].
K-means clustering gene-set enrichment
This method of gene-set enrichment is performed on two-predefined populations of samples (STK11
mutant and wildtype). A database of gene-sets is clustered into (k=2) populations using K-means
clustering through the Biopython library and the Bio.Cluster.kcluster function. The average method was
used and Euclidean distance with 100 permutations. Upon clustering into two populations by each
gene-set, a Fisher Exact test is used to statistically calculate how well the gene-set was able to cluster
the patients into the predefined subsets. The scipy.stats.fisher_exact function was used for the
statistical test.
Generation of signature scores
Principal component analysis was run through the Biopython library (https://biopython.org/) using the
Bio.Cluster pca function. The data matrix was refined to the genes of interest prior to calculating
component scores of each gene. The principal component was chosen which explained the largest
variance between STK11 mutant and wildtype patients (PC1). Component scores were averaged
between TCGA and MLOS and used for calculating a gene expression signature in each dataset.
Signature scores were generated by first calculating the number of standard deviations from the mean
(z-score) for each gene for each patient. The averaged principal component loading coefficients were
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averaged between both TCGA and MLOS for each gene and were multiplied by the z-score. This
cumulative score was then divided by the number of genes in the signature to get an average score per
gene.
Western blotting and antibodies
Antibodies were diluted to working concentrations in PBST with 5% milk. The ODC1 antibody
(ab193338), a mouse monoclonal antibody from Abcam, was used at a dilution of 1:400. The STK11
(LKB1) antibody, a rabbit monoclonal antibody from Cell Signaling (27D10) #305, was used at a dilution
of 1:1,000. The β-actin antibody (SAB1305567), from Sigma-Aldrich, was used at a dilution of 1:20,000.
The Li-COR Odyssey Fc was used to determine protein detection
(https://www.licor.com/bio/products/imaging_systems/odyssey_fc/). Blots were developed for 10
minutes using the chemiluminescent channel.
Metabolomics Analysis by LC-MS
Frozen lung tumor samples (~10 mg) were homogenized in 40 mM ammonium formate using 1.0 mm
zirconia beads in a BeadBeater (Biospec Products, Bartlesville, OK). Insoluble material was pelleted and
the protein concentration of the supernatant was used for quality control and normalization. Stable
isotope-labeled standards (SIS) including 1 mg/mL of D3-cysteine, 13C-alanine, 13C-methionine, 13Carginine, D3-serine, D3-S-(5'-adenosyl)-L-methionine (SAM) and 1 µg/mL of 13C4-putrescine, 13C5ornithine, D8-spermidine, and D8-spermine (Cambridge Isotope Labs, Tewksbury, MA) were added to
each homogenate followed by 800 µL of acetonitrile:methanol:acetone (8:1:1) to precipitate proteins. .
The supernatant containing metabolites was lyophilized, re-suspended in 50 µL water and analyzed with
LC-MS (Vanquish UHPLC and Q Exactive HF mass spectrometer, Thermo, San Jose, CA). For targeted
quantification of metabolites in the polyamine pathway, peak areas were determined using Xcalibur
QuanBrowser (v. 3.0.63) and amounts (in ng/mg total protein or mg tumor wet weight) were calculated

57

using the peak area ratio of each molecule to its respective SIS. For untargeted analysis, LC-MS data files
were converted to mzml files and analyzed using MZmine 2.25. [142]
Data processing steps for the other detected metabolites (not involved in the polyamine pathway and
without matched stable isotope-labeled standards) consisted of several steps: mass detection,
chromatogram building, smoothing, chromatogram deconvolution, grouping of isotopic peaks, peak
alignment with m/z tolerance of 5 ppm and retention time tolerance of 0.25 min, gap filling to fill in
missing peaks, duplicate peak removal, and peak filtering (retention time range 0.45–17.0 min, peak
duration range 0.06–2.00 min).
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Chapter 3: STK11 differentially impacts cell lineage switching via NKX2-1 in vivo and ex vivo with
implications for future research

Abstract
STK11 mutations are most frequently found in adenocarcinoma and large cell neuroendocrine
carcinoma of the lung, which arise from type II pneumocytes (ATII) and neuroendocrine cells,
respectively. Both of these cell types are responsible for regulating inflammatory responses. Neither the
cell lineage nor inflammatory phenotypes are preserved in model systems of STK11 loss compared to
patient tumors. STK11, a mediator of the stress response has been previously shown to impact cell
polarity, inflammatory response, metabolism, and cell lineage switching. This study evaluates the
disparate effect STK11 loss of function has on cellular differentiation in various model systems
compared to human tumors: cell lines, mouse models, and patient derived xenografts and how these
discrepancies impact our ability to accurately study inflammatory signaling and immunomodulatory
pathways in the context of STK11 loss tumors. These models of STK11 loss display decreased expression
of the ATII marker NKX2-1 compared to STK11 loss human tumors which had no significant change.
Using two well established lung adenocarcinoma cohorts TCGA and MLOS, we discover that not only do
human tumors retain their cell lineage marker NKX2-1, but a subset of patient tumors with STK11 loss of
function also express neuroendocrine lineage markers ASCL1 and CALCA. Further analysis, based on
gene expression, indicated that STK11 loss tumors can be classified into three distinct sub-groups;
classical (NKX2-1+), neuroendocrine (ASCL1+, CALCA+, NKX2-1+), and negative (triple negative). We
show that the negative subset of patient tumors with STK11 loss of function have increased PD-L1
protein, loss of urea cycle enzyme ODC1 and transporter SLC14A2 expression, loss of NKX2-1
transcriptional targets, increased rate of CDKN2A (p16) loss, and are no longer characterized by changes
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in inflammatory signaling compared to STK11 wildtype tumors. Additionally, cell line and PDX models
share similar characteristics and cluster with this classified negative subset of STK11 loss human tumors
based on gene expression patterns while mouse models for STK11 loss share almost no resemblance to
patient tumors. Two public experimental studies were used to show expression patterns based on ATII
differentiation and NKX2-1 addition. Enzymes altered by ATII differentiation and NKX2-1
complementation correlate with NKX2-1 expression in patient tumors and are absent in the negative
subset of STK11 loss patients. Taken together, we uncover that of patients with STK11 loss, a subset
lose cellular lineage through NKX2-1 and hallmarks of STK11 loss such as polyamine metabolism through
ODC1 and show that all ex vivo models mimic these characteristics of loss of cellular identity. This study
highlights the potential shortcomings of our current model systems of STK11 loss and how these
limitations need to be circumvented in order to fully understand the biology surrounding STK11 loss as it
relates to the immune response in patient tumors.

Introduction
As of 2019, lung cancer remains the leading cause of cancer death with adenocarcinoma being the most
commonly occurring lung cancer histology of the most common classification of lung cancer, non-small
cell lung cancer (NSCLC) [143]. Previously we showed that, adenocarcinoma patients with predicted loss
of STK11 upregulate polyamine metabolism driven by the rate limiting enzyme ornithine decarboxylase
(ODC1) [144]. While this phenotype was observed in patient tumors, it was not observed in cell culture,
mouse models, and human xenografts. Congruent with other studies, we noticed that loss of STK11
resulted in changes in cellular lineage and differentiation and that this change in cell state was also
associated with ODC1 expression in patients [30, 137]. Given that both STK11 loss [47-49, 145] and
polyamine metabolism [70, 71, 79] are strongly linked to immune suppression, manipulating this
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biological pathway in the appropriate context is crucial to our understanding of its impact. We therefore
sought to further understand the complexity underlying the loss of conservation of gene expression in
models of STK11 loss.
STK11, also known as LKB1, is a mediator of stress signaling altered at a frequency of over 30% in lung
large cell neuroendocrine and adenocarcinoma [40, 124]. Given that it plays a role in cell polarity,
metabolic regulation, inflammation, DNA repair, and apoptosis, it comes as no surprise that it is also
involved in cell lineage switching [30, 137, 146]. Previous genetically engineered mouse models have
shown the impact of STK11 loss on an adeno to squamous lineage switch through both SOX2 mediated
suppression [30] and epigenetic changes driven by the EZH2 polycomb recombination complex [137].
While, these observations are relevant in mice, we notice that this same lineage switch is not present in
patient tumors of STK11 loss, which maintain the histological identity of adenocarcinoma.
The cell lineage that is most commonly thought to give rise to adenocarcinoma is the type II
pneumocyte (ATII). These cells are characterized by expression of NKX2-1 (better known as TTF1, a
master transcriptional regulator expressed in thyroid, lung, and diencephalon) and pulmonary
surfactants, responsible for regulating gas exchange and injury/inflammatory response in the lung [8, 9,
22] (Figure 3.1A). Given that many genetic alterations appear in cancer in a tissue specific manner
implies the large impact cell lineage and tissue type play on cancer initiation and progression.
Neuroendocrine cells of the pulmonary vasculature act as sensors of the lung, providing feedback and
transmitting signals pertaining to the environment [31, 33, 34] (Figure 3.1A). These cells exist in
isolation or cluster into neuroepithelial bodies (NEBs) and express the lineage biomarkers ASCL1
(Achaete-Scute Family BHLH Transcription Factor) and CALCA (Calcitonin related polypeptide alpha)
[147, 148]. Serving as sentinels of abnormal lung activity, these cells are capable of sensing hypoxia
among other environmental stimuli and can both communicate to other tissues in the body as well as
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influence the local microenvironment [32]. In addition to their role in homeostatic maintenance and
signal transduction, neuroendocrine cells produce neurotransmitters such as GABA and are thought to
play a vital role in allergen response [34]. We have shown in a previous publication [144] that lung
adenocarcinoma patients with predicted loss of STK11 function show increased production of GABA, and
a decrease in inflammatory response [149, 150]. Cell lineage state is of great importance to biological
function and should be considered when utilizing model systems.
One of the most profound hurdles in our attempt to answer complex biological questions is the
development of model systems capable of accurately recapturing biology as it exists in the patient.
Attempts to conserve this biology range from the simplicity of in vitro culture all the way to syngeneic
mouse models, with many others such as xenograft models and spheroid culture. Our observation is
that lineage transitions not only occur in different contexts of STK11 loss, but that this difference could
impact the immune microenvironment. We will focus this study on dissecting the differential impact
STK11 loss has in different model systems in order to display that ex vivo models may fail to recapture
some of the most relevant aspects of lung cancer biology. These findings indicate how the current
limitations of surrogate in vivo research are hindering the discovery of novel therapeutic targets in the
realm of metabolism and immunotherapy.
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Figure 3.1
Schematic of lung progenitor differentiation into cell lineages that give rise to various histology of lung
cancer

Results
Datasets
We first used published datasets to compare the impact of STK11 loss on gene expression in vivo and ex
vivo models with an emphasis on cellular differentiation, as listed in Table 3.1. We used our previously
defined gene expression signature for STK11 loss to predict STK11 status for all studies except
genetically engineered mouse models [144]. These resources include cell line datasets GSE36133
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(Cancer Cell Line Encyclopedia or CCLE) [151], mouse models GSE21581 (MM1) [152] and GSE118246
(MM2) [30], patient derived xenograft GSE78806 (PDX) [153], and two human datasets mentioned in
our previous study MLOS [53, 127, 139] and TCGA. The CCLE contains 44 annotated lung
adenocarcinoma samples, 15 classified as STK11 mutant and 29 as wildtype. MM1 contains 18 primary
lung samples, 9 KRAS mutant and 9 KRAS/STK11 mutant. MM2 contains 8 KRAS/TP53 mutants, 9 STK11
mutant SOX2 cre, 6 STK11/PTEN mutants, 8 SOX2 overexpressed STK11 mutants, and 3 normal lung. The
PDX study contains 46 adenocarcinoma samples determined by clustering and of these 10 were
accurately called STK11 mutant and 29 wildtype. MLOS contains 442 patient tumors, 145 predicted
STK11 mutants and 297 wildtype. TCGA contains 515 lung adenocarcinoma tumors, 178 predicted
STK11 mutants and 337 wildtype. In addition to these datasets, we also explored two separate
characteristics of ATII cellular identity through viral transduction of NKX2-1 into A549 cells (STK11
mutant, NKX2-1 null) (GSE40584) and combination dexamethasone and cyclic AMP treatment of fetal
lung epithelial cells to differentiate them into ATII cells (GSE3306).
Table 3.1 Public dataset information

Dataset Name

GSE

Description

PDX
CCLE
MM1
MM2
NKX2-1
DCI

GSE78806
GSE36133
GSE21581
GSE118246
GSE40584
GSE3306

Patient Derived Xenografts
Cancer Cell Line Encyclopedia
Mouse Model #1
Mouse Model #2
NKX2-1 addition to A549 cells
ATII differentiation

Ex vivo models of STK11 loss lose ATII lineage marker NKX2-1
We characterized the expression changes of NKX2-1 in each study with respect to STK11 status, either
determined by signature or study design, in mouse models. STK11 mutant samples in MM1 (p = 0.131),
MM2 (p=6.3e-05), STK11 predicted mutants in the CCLE (p=0.0037) and PDX cohorts (p = 0.00397) had
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notable reductions in their expression of the ATII lineage marker NKX2-1 (Figure 3.2 A-B). In MM1 a
subset of KRAS mutant mouse models had reduced expression of NKX2-1, whereas all STK11 mutant
tumors displayed this reduction, explaining the decreased statistical significance. A similar observation is
made in the CCLE and PDX model, where NKX2-1 is unanimously reduced in STK11 mutant-like samples
but selectively reduced in the wildtype (Figure 3.2 C-D). We also explored the MLOS and TCGA cohort to
determine if patient tumors with predicted STK11 loss also displayed reduction of NKX2-1. While a
subset of patients had marked reduction of NKX2-1 in both the STK11 mutant-like and wildtype cohorts,
there was no change in frequency of this reduction with respect to STK11 status in both MLOS (p =
0.246) and TCGA (p=0.246) (Figure 3.2 E-F).

Figure 3.2 STK11 loss results in loss of type II pnuemocyte identity ex vivo
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(a-f) Log2 transformed expression of NKX2-1. (a) Mouse model (MM1) of n=9 KRAS tumors vs n=9
KRAS/STK11 tumors. (b) Mouse model (MM2) of n=8 KRAS/TP53 tumors and n=6 STK11/PTEN tumors.
(c) Cell Line Encyclopedia lung adenocarcinoma cell lines predicted with the STK11 loss signature cutoff
WT (n = 29) < 0 > Mutant (n = 15). (d) Patient derived xenograft models predicted with the STK11 loss
signature with a cutoff of WT (n=29) < 0, Mutant (n =10) > 0.1. (e) MLOS lung adenocarcinoma patient
tumors predicted for STK11 status with WT (n=297) and Mutant (n=145). (f) TCGA lung adenocarcinoma
patient tumors predicted for STK11 status with WT (n=337) and Mutant (n=178).
A subset of tumors with predicted STK11 loss from MLOS and TCGA also show reduced NKX2-1
expression, similar to the phenotype of all non-patient models (Figure 3.2 E-F). This provides us with an
opportunity to assess the impact of STK11 loss in the context of NKX2-1 expression both within patient
tumors and between in and ex vivo models. Previously we reported that patient tumors with predicted
STK11 loss upregulate amino acid catabolism, polyamine metabolism, and the urea cycle while
downregulating interferon mediated immune response and inflammation [144]. Remarkably, patient
tumors with both STK11 loss and decreased NKX2-1 expression lose these hallmarks as denoted by their
loss of key regulatory genes SLC14A2 and ODC1. Specifically, the urea transporter SLC14A2, a hallmark
gene of the urea cycle pathway highly correlates with NKX2-1 expression only in tumors with STK11 loss
(Figure 3.3A). Cell lines, mouse models, and PDX models of STK11 loss similarly lack NKX2-1 and also
lack upregulation of these genes (Figure 3.3B).
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Figure 3.3 Cell lineage impacts the urea cycle and polyamine pathway
(a) Correlation of the expression of the urea transporter SLC14A2 and NKX2-1 in TCGA. (b) Fold change
of ODC1 expression in each study.

Classification of STK11 loss tumors into neuroendocrine, classical, and negative subtypes

Interestingly, we noticed that a fraction of patient tumors with STK11 loss upregulated lineage
markers of neuroendocrine carcinoma such as ASCL1 (TCGA p = 8.38e-31 MLOS p = 2.19e-16)
and CALCA (TCGA p = 1.13e-54 MLOS p = 3.78e-41) (Figure 3.4). Coincident with an increase in
the abundance of the neurotransmitter GABA in tumors with STK11 loss [144], this suggests
that pathologically classified lung adenocarcinoma with STK11 loss could undergo partial
lineage switching to neuroendocrine carcinoma.
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Figure 3.4 A subset of patients with STK11 loss express neuroendocrine markers
Gene expression of neuroendocrine markers ASCL1 and CALCA in TCGA (left) and MLOS (right).

We further classified patient tumors with predicted STK11 loss based on their expression
patterns of neuroendocrine markers ASCL1 and CALCA and the ATII marker NKX2-1 through Kmeans clustering. We annotated tumors in MLOS and TCGA with high expression of ASCL1,
CALCA, and NKX2-1 as “neuroendocrine”, high expression of NKX2-1 and low ASCL1/CALCA as
“classical”, and “negative” as low expression of all these markers. In TCGA, patients clustered
into these 3 subtypes with 84 classical tumors, 68 neuroendocrine, and 26 negative (Figure
3.5A). MLOS contained 91 classical, 44 neuroendocrine, and 10 negative tumors (Figure 3.5B).
The negative cohort similarly to STK11 WT cells lacks both ODC1 and SLC14A2 expression
compared to the classical and neuroendocrine subtypes (Figure 3.5 C-D).
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Figure 3.5 Classification of STK11 loss patient tumors into neuroendocrine, classical, and negative
subsets
(a-b) K-means clustering of STK11 mutant patients in TCGA (a) and MLOS (b) into negative, classical, and
neuroendocrine subsets based on the markers NKX2-1, ASCL1, and CALCA. (c-d) Expression of ODC1 (c)
and SLC14A2 (d) in negative, classical, neuroendocrine, and STK11 WT patients in TCGA.
Molecular profiling of STK11 mutant subtypes
We characterized these cohorts by defining molecular characteristics. We analyzed gene expression,
protein expression, DNA mutations, and copy number alterations using data from the TCGA cohort and
gene expression, survival, and clinical data from both TCGA and MLOS.
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Clinical data
Clinically, there were only few notable characteristics distinguishing the 3 clusters. The negative cluster
displayed characteristics of a more aggressive disease state in TCGA. Compared to the classical and
neuroendocrine cohorts they displayed a higher T3-4 to T1-2 ratio (negative = 0.368, classical = 0.137,
neuroendocrine = 0.097) and N2 to N0 ratio (negative = 0.67, classical = 0.20, neuroendocrine = 0.21)
(Figure 3.6 A-B). No significant clinical characteristics separated the classical from neuroendocrine
cohorts.

Figure 3.6 Clinical data of STK11 loss subtypes
(a) N staging in the three STK11 loss subtypes in TCGA. (b) T staging in the three STK11 loss subtypes in
TCGA
Survival
Overall survival was assessed at 3 years (1095 days or 36 months) in the 3 subtypes through Kaplan
Meyer analysis and log-rank test (Figure 3.7 A-B). The negative cohort displayed the worst survival
compared to both the classical (TCGA p = 0.019, MLOS p = 0.00087) and neuroendocrine (TCGA p =
0.00074, MLOS p = 5.24e-7) cohorts with a median survival of less than 700 days. There was no
significant difference between the classical and neuroendocrine cohort in TCGA (p = 0.103) but the
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neuroendocrine subset had a slightly better prognosis in MLOS (p = 0.022). These data suggest that dedifferentiation and loss of cell identity is strongly associated with poor patient prognosis.

Figure 3.7 Survival curves of STK11 loss subtypes
(a-b) Kaplan Meier curves of 3 year survival in TCGA (a) and MLOS (b) based on the STK11 loss subtypes
Gene expression
We analyzed differences in gene expression patterns in both MLOS and TCGA based on our
reclassification of patients, utilizing fold changes in one vs rest and one vs one between cohorts (Figure
3.8 A). The classical cohort was characterized by elevated levels of SFTPD, ALDH3A1, HHLA2, and
SCGB3A2 with decreases in FGB and PAH. The negative cohort displayed elevated levels of DKK1, CPS1,
KYNU, SMOX, NTS, and FGA with decreases in PGC, SFTA3, NKX2-1, PRMT8, LPL, MAOA, ALDH3A2, HOPX,
ODC1, SLC14A2 and FOXA2. The negative cohort loses lineage markers associated with ATII biology,
including genes necessary for urea transport (SLC14A2) , polyamine metabolism (ODC1), and synthesis of
GABA from putrescine (MAOA, ALDH3A2). In the negative cohort there is also marked increase of the
neurotransmitter neurotensin (NTS) and polyamine catabolism in spermine oxidase (SMOX). A potent
biomarker of ex vivo STK11 loss, carbamoyl phosphate synthase 1 (CPS1), is elevated in this subset of
patients [61, 62]. The neuroendocrine cohort had elevated RET, DLL3, NEUROD1, SOX2, DDC, MYCN,
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and MYCL1 with decreases in KRT6A and INSL4, which has recently been reported to sustain growth and
viability in STK11 mutants ex vivo [154].
The most drastic changes in gene expression were associated with the negative vs classical and negative
vs neuroendocrine comparisons as the classical and neuroendocrine cohorts as more similar (Figure
3.8A). Unexpectedly, within the classical cohort is a shift in expression patterns towards characteristics
of the negative cohort, congruent with decreasing NKX2-1 expression, suggesting that de-differentiation
is a continuous process and results in changes in both transcriptional regulation and tumor
aggressiveness.
Protein
Through use of TCGA’s RPPA protein expression data we profiled the three STK11 mutant subtypes for
defining characteristics (Figure 3.8 B). In the classical cohort there was a significant reduction in cyclin
B1 (CCNB1), glutamine dependent asparagine synthetase (ASNS), caspase 7 cleavage, and
immunosuppressive programmed cell death 1 ligand 1 (PD-L1). There was a significant increase in
napsin A which is involved in the processing of surfactants, HER3, and YAP pS127 which lies downstream
of AMPK activation and is activated during high cellular density. The negative cohort had significant
increases in glucose-6-phosphate dehydrogenase G6PD and hallmark of NRF2 activation, TFRC, cyclinE1
and had the highest levels of both PD-1 and PD-L1 expression. There was a reduction in TTF1 (NKX2-1),
c-KIT, and IGFBP2. Through both gene and protein expression there is a remarkable correlation of KIT to
NKX2-1 levels. KIT is highly mutated in gastrointestinal cancers [155], is highly associated with STK11
loss and may be related to gastrointestinal signaling mediated through NKX2-1 otherwise repressed by
STK11 [28]. The neuroendocrine cohort was characterized by elevated IGFBP2, XRCC1, BCL2, acetyl-atublin lys40 with decreases in YAP pS127.
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Figure 3.8 Gene expression and protein expression of STK11 loss subtypes
(a-b) Heatmap of Z-score (scale -3 to 3) transformed gene expression (a) and protein RPPA (b) changes
in TCGA in the three STK11 loss subtypes.
Mutations
The three subtypes did not have drastic alterations in mutational profiles (Figure 3.9A). However, TP53
and SMARCA4 [156-158]mutations were more prominently associated with the negative cohort. KRAS
mutations were seen in both the classical and neuroendocrine subsets at increased rates relative to the
negative cohort. SMARCA4 (BRG1) is known for its role in Rb signaling and chromatin remodeling and is
found at the same chromosomal locus as both KEAP1 and STK11 (19p13), which is commonly lost in lung
adenocarcinoma. Interestingly, conservation of TP53 and p16 signaling have both been associated with
neuroendocrine characteristics [147] and NKX2-1 signaling [27, 67]. The neuroendocrine cohort had
increases in ATM mutations and decreases in NRF2 activating mutations of KEAP1/NFE2L2, which are
seen in high statistical co-occurrence with STK11 mutant tumors [52].
Copy number
Gene copy number profiles showed very interesting lineage specific amplifications (Figure 3.9B). The
neuroendocrine cohort displayed copy number amplifications of the NKX2-1/FOXA1 locus, suggesting
that amplification of NKX2-1 may have an oncogenic role in this subset. NKX2-1 and FOXA1 have been
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shown to have opposite roles in the regulation of differentiation and lung cancer progression [28, 29].
CDKN2A (p16), had an increased rate of deletion in the negative cohort, followed by the classical, and
much less so in the neuroendocrine subset. While MYC was amplified in each cohort, it was most
commonly amplified in the neuroendocrine subset.

Figure 3.9 Mutational frequency and copy number alterations of STK11 loss subtypes
(a) Mutational frequency of canonical mutations in lung adenocarcinoma between the three STK11 loss
subtypes and STK11 wildtype patient tumors. (b) Heatmap of Z-score transformed copy number changes
(scale -3 to 3) between the three STK11 loss subtypes.
GSEA of STK11 loss subtypes reveals role of cell lineage on immune response
Gene set enrichment was performed on each subtype compared to STK11 WT tumors in both MLOS and
TCGA. Genes changing by +/- 1.5 fold with a p-value of less than 1e-10 were kept; except for in the
negative vs WT comparison of MLOS as a p-value of less than 1e-7 was used due to sample size
limitations. The classical cohort contained 335 genes in MLOS and 734 genes in TCGA with 218 of these
genes overlapping. GSEA analysis on these 218 genes revealed the top hallmarks of interferon alpha
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response (FDR = 4.73e-8), interferon gamma response (FDR = 1.1e-6), fatty acid metabolism (FDR =
1.16e-6), and inflammatory response (FDR = 6.41e-6) (Figure 3.10A). The neuroendocrine cohort
contained 426 genes in MLOS and 1399 with 315 overlaps. GSEA analysis resulted again in interferon
gamma (FDR = 1.41e-13) and alpha response (FDR = 7.11e-11), inflammatory response (FDR = 1.54e-8)
as well as late estrogen response (1.54e-8) (Figure 3.10B). Finally, the negative cohort contained 364
genes in MLOS and 901 in TCGA with 155 overlaps. Hallmarks for the negative cohort are vastly different
than the others, as seen through hallmarks of xenobiotic metabolism (FDR = 1.92e-4) and coagulation
(FDR = 1.92e-4) (Figure 3.10C) being the top pathways altered. Only 14 genes out of a total of 688
overlap between the 3 cohorts (2.03%) with the most unique cohort being negative, overlapping with
classical in 15 out of 373 (4.02%) genes and neuroendocrine with 9 out of 470 (1.91%). Neuroendocrine
and classical subtypes overlap with 78 out of 533 (14.6%) genes, displaying that their biology is more
readily conserved between them (Figure 3.10D). As expected, the negative cohort loses inflammatory
and interferon signaling, partially elucidating the role of cell lineage in the immune suppressive
phenotype of STK11 loss.
Two gene expression signatures explain the changes between lineage states
In order to describe the variance in expression patterns seen between subtypes we performed principal
component analysis on the most variant genes. Two principal components sufficiently explain this
variance with PC-1 describing neuroendocrine features and PC-2 describing features of NKX2-1 loss
(Figure 3.10E). Loading coefficients of genes most significantly contributing to PC-1 include CALCA,
ASCL1, KLK12, PCP4, CTNND2, RET, and NEUROD1. Top coefficients of PC-2 include PCSK2, GKN2,
C16ORF89 (LINC00473), SLC14A2, NAPSA, NKX2-1, LPL, and HOPX.
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Figure 3.10 ATII cell lineage loss results in loss of inflammatory signaling
(a-c) MSigDB GSEA of (classical (a), neuroendocrine (b), and negative(c)) vs WT consensus genes. (d) 3way Venn diagram of consensus gene expression changes in both MLOS and TCGA of each STK11 loss
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subtype compared to STK11 WT. (e) Scatter plot of PC-1 and PC-2 of Principal component analysis
performed on 544 genes describing variance of STK11 loss subtypes.
ATII differentiation upregulates surfactants and neuroendocrine enzymes
In order to distinguish the changes that take place as a result of type II pneumocyte differentiation we
explored a public dataset in which human fetal lung epithelial cells were differentiated into type II
pneumocytes through treatment with dexamethasone and cyclic AMP [159]. Since many characteristics
of type II pneumocytes are lost in ex vivo studies as well as in a subset of patients, it is important to see
what genes are directly regulated through the differentiation. A student’s t-test was performed on the
dataset comparing the 5 treated samples to untreated and changing genes were displayed through
volcano plot (Figure 3.11A). In the treated cohort, significant upregulation was seen in ALDH3A2, SFTPC,
SFTPB, CIT, CALCA, HOPX, NR4A2, LPL, PGC, and MAOA. Reductions in PLAU, GABBR1, TP63, HLA-DRB4,
SLC7A2, and PTGS2 were also observed. Many of these genes upregulated during ATII differentiation
play critical roles in ATII cell biology and are seen in neither ex vivo models nor the negative cohort of
patients with STK11 loss. GSEA was performed on significantly changing genes and resulted in the
hallmarks of late (FDR = 2.16e-12) and early (FDR = 5.34e-8) estrogen response, KRAS signaling (FDR =
2.32e-11), apical junction (FDR = 5.34e-8), and TNFa signaling via NFKB (FDR = 5.34e-8) (Figure 3.11C).
Given that cells were treated with a corticosteroid (dexamethasone), estrogen response was not
surprising. However, KRAS signaling and inflammatory pathways are observed to change upon ATII
differentiation and describe the function of type II pneumocytes to repair upon injury and mediate lung
inflammation.
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Figure 3.11 ATII differentiation and NKX2-1 addition share transcriptional changes associated with
STK11 signaling
(a) Volcano plot of gene expression changes as a result of type II pneumocyte differentiation. (b)
Volcano plot of gene expression changes as a result of NKX2-1 addition to A549 cells. (c-d) GSEA of
genes changing as result of ATII differentiation (c) and NKX2-1 addition (d).

Overexpression of NKX2-1 in A549 cells partially restores in vivo phenotype
A previous publication used a lentivirus to overexpress NKX2-1 in NKX2-1 null A549 cells [160]. This cell
line was derived from lung adenocarcinoma and is used as a model of alveolar type II cells. They have
been shown to have loss of function of STK11 by DNA-sequencing and gene expression patterns with an
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activating mutation in KRAS. While these characteristics mimic that of a common patient tumor lacking
STK11, these cells are negative for the type II marker NKX2-1, making them an interesting candidate for
the complementation of its expression. Student’s t-test was performed on the gene expression of this
dataset to explain the variance between these A549 cells determinate of NKX2-1 status (Figure 3.11B).
Notable increases in gene expression include: CD274 (PD-L1), KIT, SFTPB. ODC1 was also slightly
upregulated upon treatment. Decreases in PTGS2 (COX2), FGA, and HLA-DMB was observed. The
complementation of NKX2-1 to A549 cells restored a subset the observed patterns of gene expression
seen in patients with STK11 loss including increases in KIT and decreases in class II HLA’s. Unexpectedly
there is a remarkable increase in PD-L1 expression, opposite to the patient phenotype of STK11 loss.
Recently, a study suggested that the anti-sense transcript of NKX2-1 is responsible for the repression of
CD274 [161]. Perhaps the regulation of PD-L1 lies on a balance between NKX2-1 and its anti-sense
transcript (NKX2-1-AS1), of which is not transcribed from the lentiviral construct. This dataset displays
the role that the NKX2-1 transcription factors plays in the context of STK11 loss and highlights its
importance in regulating the expression of several genes lost in ex vivo studies.
Differentially expressed genes from this study were filtered by a p-value of less than 1e-5 with an
absolute fold change of more than 1.5. The remaining 360 genes were used for gene set enrichment
(Figure 3.11D). Complementation of NKX2-1 revealed an increase in epithelial to mesenchymal
transition (FDR = 1.16e-29), hypoxia (FDR = 9.42e-26), TNFa signaling via NFKB (FDR = 1.39e-20),
upregulation of KRAS signaling (FDR = 6.37e-17), and inflammatory response (FDR = 6.37e-17). These
hallmarks display the significant impact that NKX2-1 plays in metastasis, sensing of oxidative stress, and
immune responses that are lacking in ex vivo models of STK11 loss.
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STK11 loss subtype signatures are altered in both NKX2-1 addition and ATII differentiation
We applied the principal component derived signatures explaining the variance between subtypes of
STK11 loss to the studies of both NKX2-1 addition to A549 cells and ATII differentiation. In both the
NKX2-1 study (p=0.244) and ATII differentiation study (p=0.200) PC-1 was not significantly altered. PC-2,
the component lost in the negative cohort of STK11 loss tumors, was significantly increased in both the
A549-NKX2-1 (p=0.00079) and differentiation study (p=1.45e-6) (Figure 3.12 A-B). This displays that
NKX2-1 associated transcriptional activity conserved in a majority of patients is upregulated upon either
the restoration of NKX2-1 expression in NKX2-1 null A549 cells or the differentiation of lung fetal
epithelial cells to ATII cells. Further, a large number of gene expression changes are conserved between
both studies with a fold change exceeding +/- 1.5 and p-value of less than 0.001, suggesting that NKX2-1
plays significant role in ATII differentiation (Figure 3.12C).
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Figure 3.12 Component scores in ATII and NKX2-1 studies
(a) Boxplot of PC-1 (left) and PC-2 (right) in NKX2-1 addition study. (b) Venn diagram of genes changing
between ATII differentiation and NKX2-1 addition. (c) Correlation matrix of genes altered between
STK11 subtypes in TCGA.

STK11 negative cohort clusters with ex vivo models
We characterized gene expression patterns conserved between studies, represented by the 5-way Venn
diagram displaying overlaps of genes changing by either +/- 1.5 fold (Figure 3.13A). Using the log2 gene
expression changes in each public dataset used in this study, a matrix was created for every gene that
had expression data. In both MLOS and TCGA, we added the relative fold change from the classical,
neuroendocrine, and negative cohort compared to STK11 WT patients along with the average for all
patient tumors with predicted STK11 loss vs WT. Each study was hierarchically clustered based on genes
that were used to the describe subtype variance in PC-1 and PC-2 The neuroendocrine, average, and
classical cohort all cluster together from each study while the negative cohorts cluster with both PDX
and CCLE models of STK11 loss (Figure 3.13B). More surprising is that mouse models of STK11 loss
exhibit the least resemblance to STK11 mutant patient tumors and cluster alongside the experimental
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studies. Genes consistently lost in ex vivo models are ones with overlapping characteristics of both
neuroepithelial cells as well as type II pneumocytes such as: dopamine decarboxylase (DDC), ornithine
decarboxylase (ODC1), calcitonin related peptide alpha (CALCA), monoamine oxidase (MAOA), thyroid
transcription factor (TTF1) NKX2-1, surfactants A-D, lipoprotein lipase (LPL), and progastricsin (PGC). The
similarity of cell line and PDX models of STK11 loss to patients with loss of cell lineage displays that ex
vivo models of STK11 loss fail to maintain cellular identity as seen in a majority of patients.
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Figure 3.13 Ex vivo models of STK11 loss cluster with and mimic the negative subset of STK11 mutant
patients lacking inflammatory signaling.
(a) 5-way Venn diagram of average STK11 loss vs WT, cell lines (CCLE), patient derived xenografts (PDX),
and mouse models (MM1 and MM2). (b) Hierarchical clustering of gene expression fold changes of each
study. TCGA and MLOS were further divided into fold changes of subtype vs WT and average vs WT.
Genes selected were used for PCA signature generation.
Discussion
Here we show that STK11 loss of function results in changes in cell lineage markers unanimously in
model systems and that these cell lineage transitions influence immunomodulatory signaling. We first
profiled several known in vivo and ex vivo datasets in the context of STK11 loss. We showed the specific
loss of cellular identity in ex vivo models of STK11 loss through NKX2-1 expression, while revealing that a
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majority of patient tumors retained this identity. In addition, we observed the enrichment of
predominant neuroendocrine characteristics in a subset of in vivo STK11 loss tumors through expression
of ASCL1 and CALCA. We clustered patients into 3 subsets dependent upon their expression of lineage
markers into ATII-like (classical), ASCL1/ CALCA positive (neuroendocrine), and loss of lineage (negative).
These cohorts were then analyzed for recurrent changes in copy number alterations, protein expression,
mRNA expression, DNA mutation profiles, and overall survival. Negative cohorts displayed loss of ATII
identity and subsequently other hallmarks of STK11 loss via urea cycle utilization, polyamine
metabolism, and an increase in inflammatory response. An additional two datasets were used to
confirm the impact of NKX2-1 in the context of STK11 loss and genes modified by ATII differentiation via
dexamethasone and cyclic AMP treatment. The negative patient cohort displayed gene expression
patterns most similar to cell line and PDX models of STK11 loss and clustered separately from the
neuroendocrine and classical cohorts.
It is important to understand the differences in the nature of each of these models. The total tumor
distribution of each of the observed subtypes of STK11 loss has not been determined. It is possible that
these diverse genetic subpopulations exist in regions of the tumor; contributing to intra-tumor
heterogeneity. They could even collaborate with one another or rather they could exist as a more
homogenous and universally dispersed cell type. Cell lines, mouse models, and PDX models are much
more homogenous than most human tumors with a much quicker initiation in the case of PDX and
mouse models. Being a mediator of energy sensing and metabolic stress, STK11 loss in environments
with vastly altered resource and nutrient availability likely contribute to the significant alterations in
both cellular differentiation and gene expression seen in in vitro culture. Culture conditions most
commonly provide an excess of amino acids and sugar and are grown at normoxia (20% O2), all of which
are significantly different from in vivo models. Most surprising is how far mouse models miss the mark
of recapturing patterns of human gene expression changes. In this setting, most environmental stressors
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such as oxygen availability, immune response, and lung specific signaling should remain intact. It is
possible that studies that do not specifically target NKX2-1 positive cells with the induction of STK11 loss
could result in a tumor with mixed histology given the low frequency of ATII cells to other cell types.
Mouse models differ significantly in tumor initiation from that of patient tumors, which undergo a much
more stringent and elaborate adaptive process in disease progression. Further, another explanation of
the discrepancy of cell line and PDX models is a selection for the most aggressive phenotype of STK11
loss, which happens to be cells lacking ATII identity.
One critical factor missing from these studies is that nearly all patients with STK11 loss also have a
history of smoking [162, 163]. It is possible that environmental stress mixed with chronic tobacco
inhalation is significantly contributing to the variance of patient tumors compared to the ex vivo models.
Nicotine serves as an agonist to the stimulatory nicotinic acetylcholine receptors and plays a role in
neurological function [164, 165]. Given that we observe a significant increase of neuroendocrine like
features in patients with STK11 loss, smoking is a likely a missing piece to this puzzle. Chronic tobacco
use would result in chronic inflammation in the lung [166, 167], creating a selective pressure to not only
overcome this inflammation but to process many of the neurotoxic and ammonia containing reagents in
tobacco. Gene expression patterns allude to this selective demand through the upregulation of both
urea cycle enzymes ODC1 and CPS1 and the urea transporter SLC14A2. STK11 mutations are found in
large cell neuroendocrine and adenocarcinoma at a frequency that far surpasses other cancer types.
These observations suggest that STK11 loss may fit a very unique niche of selective adaptation to
tobacco distinct to cellular lineage. Both neuroendocrine and ATII cells modulate the inflammatory
response of the lung and have been linked to conditions such as chronic obstructive pulmonary disease,
allergy, and asthma [168-170]. These two cell types are also the ones responsible for the initiation of
large cell neuroendocrine and adenocarcinoma respectively.
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An interesting observation made is that ATII differentiation greatly upregulates enzymes required for
GABA synthesis from putrescine, another neuroendocrine-like feature. These enzymes include
monoamine oxidase (MAOA), required for the conversion of n-acetyl putrescine to n-acetyl GABAaldehyde and aldehyde dehydrogenase (ALDH3A2) required for the conversion of n-acetyl GABAaldehyde to n-acetyl GABA [96, 100]. The precursor substrate for this pathway is the synthesis of
putrescine from ornithine through ODC1, seen to be elevated only in tumors with STK11 loss that
preserve their ATII phenotype. Further, GABA has been linked to be an immunomodulatory and
suppressive agent in many studies and could explain the differences in inflammatory response seen
between STK11 loss subtypes [91, 93, 94, 96, 97].
Previous studies of STK11 loss claimed that neutrophils modulate the immune microenvironment and
result in lack of immunotherapy efficacy through an increase in proinflammatory cytokines CXCL7, GCSF, and IL-6 [145]. While these observations are true of mouse models, these same markers are not
seen to be elevated in patient studies nor do we observe any significant changes in myeloid cell
populations through gene expression patterns. Flow cytometry of patient tumors with STK11 loss
revealed that of all basic immune cell populations, t-cells were the most significantly reduced cell
population [48]. This study was carried out in mice with genetic backgrounds of KRAS/TP53 and
KRAS/TP53/STK11. We observed that TP53 mutations were enriched in the negative cohort of patients
with STK11 loss (Figure 3.9A) and previous publications have shown the dichotomy of NKX2-1 signaling
dependent on TP53 status and STK11 loss [27, 67]. Additionally, it has been shown that TP53 and p16
alterations are exclusive for subsets of large cell neuroendocrine carcinoma with dual KRAS/STK11
mutation [134]. TP53 mutations are exclusively associated with both KRAS and STK11 mutations in lung
adenocarcinoma and this could play a role in the maintenance of both cell state and subsequently
inflammatory signaling.
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NKX2-1 has historically been associated with lung adenocarcinoma and is commonly used as a clinical
marker [21]. What is most fascinating is its duality of both an oncogene and tumor suppressor
dependent on context [22]. Loss of NKX2-1 is associated with a poor prognosis and more aggressive
disease state. However, in our neuroendocrine cohort we observed amplification of the chr14q13 locus
where NKX2-1 resides. This further supports the role of NKX2-1 as an oncogene and tumor suppressor
dependent on cell lineage. We notice a strong association between NKX2-1 and loss of PD-L1 (CD274)
expression. In A549 cells, when NKX2-1 is added back, PD-L1 is one of the most significantly elevated
genes. However, the opposite trend remains true of patients with STK11 loss, in which PD-L1 is
significantly lower than tumors of other genetic background. Recently, a study determined that the
anti-sense strand of NKX2-1 (NKX2-1-AS1) is responsible for repressing PD-L1. Likely, STK11 plays a key
role in signaling both up and downstream of NKX2-1 and is determined by the equilibrium of NKX2-1 and
NKX2-1-AS1.
Model systems are created with the purpose of deepening our understanding of patient biology and
thus providing a mechanism towards discovering therapies to be used in our fight against cancer. This
study highlights the importance of having model systems that are not only capable of manipulation, but
also ones that accurately recapitulate patient biology, especially in the context of immunotherapy.
Understanding the limitations of such systems will help to not only keep an open mind to previous failed
treatments but also to improve our current models in a way that accurately depicts the disease we are
attempting to eliminate. Tissue specificity influences the frequency of genomic aberrations, as
confirmed from the diverse landscape of genomic alterations in specific cancer types. With respect to
lung cancer and STK11 loss, we hope that this consideration will drastically alter the ways in which we
study this unique genetic abnormality and provide insight into the lack of immune response in this
cohort.
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Materials and Methods
Acquisition of public datasets
Public datasets were acquired through NCBI GEO DataSets (https://www.ncbi.nlm.nih.gov/gds/) and
series matrix files were downloaded. Datasets that contained linear gene expression were log2
transformed. The individual datasets with GSE numbers are provided in Table 4.1. TCGA data was
downloaded from the Xena browser (https://xenabrowser.net/hub/) for gene expression (RNA-seq),
protein expression (RPPA), copy number variants and somatic mutation. MLOS (GSE72094) has been
previously described [53].
Hierarchical Clustering
Hierarchical Clustering was performed using the Python programming language. The gene expression
matrix was first Z-score transformed for each gene. Distance was calculated through
scipy.spacial.distance.pdist using the Euclidean distance metric. Linkage was then calculated through
scipy.cluster.hierarchy.linkage using Ward linkage. Dendrograms were created for the clustering of both
samples and genes and represented using scipy.cluster.hierarchy.dendrogram. Heatmaps were
displayed on a color bar scale by Z-score from -3 to 3.
Principal component analysis and signatures
Principal component analysis was run through the Biopython library (https://biopython.org/) using the
Bio.Cluster pca function. The data matrix was refined to the genes of interest prior to calculating
component scores of each gene. Signature scores were generated by first calculating the number of
standard deviations from the mean (z-score) for each gene for each patient. The averaged principal
component loading coefficients were multiplied by the z-score for that same gene. This cumulative
score was then divided by the number of genes in the signature to get an average score per sample.
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K-Means clustering
K-means clustering was used to classify the three STK11 loss subtypes through the Biopython library and
the Bio.Cluster.kcluster function was utilized to generate (k=3) clusters. The average method was used
and Euclidean distance with 100 permutations.
GSEA
Gene Set Enrichment Analysis was performed by using Broad Institute’s Hallmark gene-sets
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) with a FDR cutoff of 0.05.
Venn diagrams
Venn diagrams were generated using (http://www.interactivenn.net/) as referenced [171].
Kaplan Meier curves
Kaplan Meier survival curves were generated using pythons lifelines library
(https://lifelines.readthedocs.io/en/latest/). The KaplanMeierFitter was called and passed vital status
information as (alive = 0) and (death = 1) and respective survival duration. Log-rank assessment was
performed using the logrank_test in the lifelines library.
Statistical Tests
Statistical analysis was performed using the Scipy python package and the function scipy.stats.ttest_ind
for p-value between arrays. Pearson correlation was calculated through the scipy.stats.pearsonr
function. The scipy.stats.fisher_exact function was used for the statistical test determining the
significance between mutations occurring in each STK11 loss subset compared to STK11 WT.
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Chapter 4: Biomarkers, vulnerabilities and molecular characterization of STK11 loss

Abstract
STK11 loss occurs in 30% of lung adenocarcinoma patients. Being able to identify patients with this
genetic abnormality as well as understand its role in tumor progression is of great importance. In this
study we add STK11 back to cell lines with STK11 loss of function: A549, NCIH1437, and NCIH1944. We
attempt to recapture increases in expression of ODC1 as a result of STK11 loss. We determine that this
hallmark of STK11 loss biology is not sufficiently captured in vitro. Additionally, we discover that STK11
loss in vitro provides resistance to hypoxic signaling through cobalt chloride treatment, sensitivity to
immune response through interferon gamma, and impacts the sensing and uptake of nutrients glucose
and glutamine. We additionally explored siRNA of STK11 in STK11 wildtype cell lines maintaining ATII
identity as well as mouse xenograft models of A549 EV and 50kD wildtype cells. Neither of these models
were capable of recapturing gene expression changes as they occur in vivo. Finally, through IHC we
confirm that KIT is a biomarker of STK11 loss in vivo and could have clinical use in the detection of
patients with STK11 loss of function.
Introduction
STK11 loss of function occurs in over a third of lung adenocarcinoma patients. With such a high
prevalence it is important that we uncover vulnerabilities resulting from its absence. Mutations in
STK11 are associated with lack of immune infiltration and response to immunotherapy [47-49, 65, 66,
172]. One of the pathways altered by STK11 and suspected to mediate this lack of immune response is
the polyamine pathway driven through the rate limiting enzyme ornithine decarboxylase I (ODC1).
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Oddly, only in patient tumors does ODC1 remain elevated as a result of STK11 loss, making it difficult to
study and manipulate outside the human body. This study focuses on attempts at restoring the STK11
loss phenotype of polyamine metabolism in vitro while uncovering potential vulnerabilities of STK11
loss. In order to accomplish this we successfully cloned STK11 and ODC1. Throughout this study we use
qPCR, western blotting, viability assays, and Seahorse metabolic flux assays to determine the impact of
various treatments and conditions on our genetically modified cell lines.
Utilizing the following STK11 mutant cell lines: A549, NCI-H1437, and NCI-H1944, we added back wild
type STK11 and used these as direct controls. Since STK11 loss has such a strong role in metabolic
regulation, we believe that changes in culture conditions could explain the discrepancies between
patient tumors and cell lines. We modified glucose, amino acid, fetal bovine serum (FBS), and oxygen
concentrations in attempts to recapture the in vivo phenotype of polyamine biosynthesis and amino
acid catabolism. Given that polyamine metabolism overlaps with the methionine salvage pathway [98,
173] and methylation [83] we manipulated methionine and cysteine levels individually and combined
with glutamine availability to determine if this would shift metabolic flux through the polyamine
pathway. Other experiments focused on prolonged fasting, glucose deprivation, and amino acid
starvation in the context of STK11 loss.
In addition to modifications to cellular nutrient availability we explored a myriad of drugs capable of
recapturing in vivo biology such as: interferon gamma, dexamethasone, and cobalt chloride. Interferon
gamma, is a pleiotropic molecular that has been shown to have apoptopic, antiproliferative, and
antitumor effects [174, 175]. It is released by immune cells during periods of cytotoxic and
proinflammatory response and is significantly decreased in STK11 mutant tumors. Cobalt chloride is a
synthetic stabilizer of HIF1A and inducer of hypoxia [176, 177]. Dexamethasone is a corticosteroid and
has been associated with cellular differentiation of type II pneumocytes in the lung [178, 179]. Finally,
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we identify novel biomarkers capable of predicting in vivo STK11 loss and attempt to explore these
biomarkers in vitro.
Results
Cloning of STK11 and ODC1
In order to modulate the expression of our genes of interest, we cloned cDNA sequences of STK11 and
ODC1 into lentiviral vector with expression driven through the cytomegalovirus (CMV) promoter. This
construct was further transduced into A549 cells to generate 4 unique cell lines, A549 STK11 (50kD WT),
A549 STK11 (42kD) lacking a kinase domain, A549 Empty Vector (EV), and A549 ODC1. We validated
successful cloning through western blot of A549 cells with both STK11 and ODC1 running at roughly
50kD as expected (Figure 4.1). The A549 STK11 42kD was not used further in experimentation.

Figure 4.1 Validation of cloning of STK11 and ODC1 in A549 cells
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A549 cells transduced with empty vector (EV), ODC1, STK11 42kD lacking a kinase domain, and STK11
50kD wildtype protein.
STK11 alone doesn’t influence ODC1 expression in A549 cells
One of our first observations was that stable transduction of STK11 mutant cell lines with wild type
STK11 did not result in gene expression changes seen in patient tumors, most notably in ODC1.
Likewise, biomarkers such as LINC00473 were drastically reduced through expression of wild type STK11
(Figure 4.2). We validated this lack of gene expression change through western blotting and discovered
that ODC1 protein levels did not increase as a result of STK11 loss and were slightly elevated in the wild
type. Since STK11 is a mediator of metabolism and the stress response, we explored various stressors in
order to recapture and study this patient phenotype.

Figure 4.2 STK11 addition to mutant cell lines does not restore patient phenotype
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Diminished nutrients does not alter ODC1 expression in vitro
Given that STK11 is a sensor of low energy, we hypothesized that prolonged growth in tissue culture
medium, diminished amino acid availability, glucose levels, or fetal bovine serum could explain
differences in ODC1 expression. Since tissue culture media such as RPMI or DMEM contain much higher
levels of nutrients than those seen in a tumor, we explored the impact that different nutrients could
have in STK11 dependent regulation of expression. To our surprise, prolonged growth in unchanged
tissue culture media for up to two weeks did not result in changes in ODC1 expression in an STK11
dependent manner in NCIH1437 cells (Figure 4.3). Glucose, amino acid levels, and fetal bovine serum
were also not sufficient to recapture ODC1 overexpression seen in patient tumors. KIT, a common
marker of STK11 loss was also assessed as it was also not increased in cell lines as a result of STK11 loss.

Figure 4.3 Fasting does not restore patient phenotype in cell line constructs

STK11 loss sensitizes cells to interferon gamma treatment
We treated A549 cells with interferon gamma to assess the impact on cell viability, gene expression
changes and protein changes of ODC1. First, dose response curves were generated by measuring
changes in total cell count, using the Celigo for counting of viable cells. From 5ng/mL upwards there is a
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significant reduction in both the A549 EV and ODC1 constructs relative to the 50kD STK11 in total viable
cells relative to control. There was fairly consistently a difference of 20% in cell viability at all
concentrations exceeding 5ng/mL of interferon gamma at both 48 and 96 hours (Figure 4.4A-B).

Figure 4.4 Sensitivity of A549 cells to Interferon gamma at 48h
(a-b) A549 cells (EV, STK11 (50kD), and ODC1) treated with varying concentrations of interferon gamma
at 48 hours (a) and 96 hours (b)

Interferon gamma increases ODC1 expression but not protein in STK11 loss cells
Using the viability assay we determined a functional concentration of interferon gamma that displayed
changes between A549 EV (mutant) and STK11 (50kD wildtype). We then treated the cells for 48 hours
with 25ng/mL interferon gamma and isolated both protein and RNA. We ran western blots and qPCR to
test for changes in ODC1 protein and gene expression. In addition to interferon gamma, we explored
the impact that DFMO, an irreversible inhibitor of ODC1, would have on its expression in either single or
combination treatment with interferon gamma. Interestingly, interferon gamma caused an increase in
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ODC1 gene expression in the STK11 mutant A549 EV, but a significant reduction in protein expression
relative to the wild type (Figure 4.5A-B). As expected, DFMO caused a feedback response of an increase
in ODC1 protein (Figure 4.5A). LINC00473 was used to validate STK11 function in vivo as seen in Figure
4.5B.

Figure 4.5 Interferon gamma increases ODC1 gene expression but not protein in STK11 loss A549 cells
(a) Western blot of A549 variants treated with 25ng/mL interferon gamma, DFMO, and combination of
both (b) qPCR of A549 cells treated with 25ng/mL interferon gamma at 48hours
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STK11 loss provides resistance to hypoxic signaling
We sought to explore the possibility that the induction of hypoxic response could be a factor
distinguishing in vivo models from those in vitro. Cobalt chloride is used to stabilize HIF1A and induce a
hypoxic response. We hypothesized that since atmospheric oxygen is at a concentration of nearly 20%
while tumors range from 1-5% that this change could result in changes to oxidative stress response
pathways such as polyamine metabolism. We treated both A549 and NCIH1944 cells with (1x = 500uM)
Cobalt chloride for 48 hours at concentrations varying by 3 fold and 2 fold respectively. In both
instances, the mutant empty vector had a significant increase in viability relative to the STK11 wildtype
(Figure 4.6A-B).

Figure 4.6 STK11 loss provides resistance to hypoxic signaling through cobalt chloride
(a-b) A549 (a) and 1944 (b) cells at 48hours treated with cobalt chloride

Glutamine is required for ODC1 protein expression dependent of STK11 loss
Glutamine is an amino acid essential for cellular growth in vivo, and is also the precursor of ornithine
synthesis through the enzyme ornithine aminotransferase (OAT). We hypothesized that perhaps the
increased ODC1 levels seen in patients was due to the scarcity of precursors of either polyamine
metabolism or methionine salvage through methionine and cysteine. In order to further dissect the
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impact of these metabolites, we cultured A549 cells in dialyzed FBS with media lacking glutamine,
methionine, and cysteine. We added back each of these metabolites and grew cells for 48 hours.
Shockingly, in media conditions lacking methionine and cysteine but with added glutamine, ODC1
protein expression was elevated in the mutant EV cells but not in the wildtype (Figure 4.7). Upon
removal of glutamine, ODC1 protein was also reduced in the EV cells.
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Figure 4.7 Glutamine in the absence of methionine and cysteine increases ODC1 protein in A549 cells
with STK11 loss
(a) Western blot of A549 cell variants EV and 50kD STK11 wildtype 48 hours following the above nutrient
conditions (b) qPCR of the RNA harvested from the same conditions in (a)

STK11 loss impacts glutamine sensitivity
To further study the relevance of glutamine sensitivity in the context of STK11 loss, we subjected A549
cell line variants to seahorse assays to determine the impact of glutamine on oxygen consumption and
metabolic capacity. Glutamine injections increase the relative oxygen consumption of A549 EV cells at a
much more rapid rate than cells with wildtype STK11 (Figure 4.8). This suggests that STK11 loss either
allows for the more rapid consumption of glutamine or heightens the cells sensitivity to its withdrawal.

Figure 4.8 STK11 loss increases glutamine uptake and dependence
Seahorse assay with the injection of glutamine to a final concentration of 1mM in A549 EV and 50kD
STK11 wildtype cells
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STK11 loss impacts nutrient sensing
We next wanted to determine whether or not STK11 loss had an impact on the sensing and uptake of
available nutrients from the environment. In order to answer this question, we serially diluted both
glutamine and glucose levels in a 96 well plate for both the STK11 EV mutant and 50kD wildtype A549
cell lines. Both cell lines had decreased cellular growth upon diminishment of either glucose or
glutamine. However, what was remarkable was the rate at which the 50kD wildtype cell line was able to
properly sense nutrients at a lower concentration (Figure 4.9 A-B). This suggests that STK11 loss hinders
a cells ability to detect low levels of nutrients and instead allows them to grow at an optimum rate as
long as they are above a minimum threshold. This could partially explain the increase in oxygen
consumption seen earlier through glutamine injection, as STK11 loss could serve to lift inhibitory
mechanisms of metabolic capacity.

Figure 4.9 STK11 loss impairs low concentration sensing of glucose and glutamine
(a-b) Relative viable cells compared to control at 48 hours with altered glutamine concentrations and
glucose concentrations relative to normal media in A549 EV cells (a) and STK11 wildtype (b)
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siRNA of STK11, KEAP1, and NKX2-1 in H441 cells
In order to circumvent the cell lineage loss mentioned in chapter 3, we identified a cell line (NCIH441)
that maintained cellular identity through NKX2-1. This cell line was wildtype for STK11 and had a known
mutation in TP53. We utilized a siRNA for both STK11 and KEAP1 to determine whether knockdown of
STK11 in a cell line that maintained ATII identity would increase ODC1 expression (Figure 4.10). KEAP1
siRNA was used as a control to elucidate the role of STK11 loss, given that these two mutations have
high co-occurrence in lung adenocarcinoma. Cell pellets were harvested at 24, 48, 72, and 96 hours
following siRNA treatment. At 96 hours, STK11 was almost undetectable by western blot. However,
there was no increase in ODC1 or KIT, both of which are biomarkers of STK11 loss in vivo. There was no
notable change in NKX2-1 expression following knockdown of STK11. Knockdown of KEAP1 resulted in
partial reduction of NKX2-1. We conclude that knockdown of STK11 through siRNA is either not capable
of mimicking the STK11 loss phenotype or that this model system still falls short of recapturing patient
biology.

Figure 4.10 siRNA of NCIH441 cells for STK11 and KEAP1
101

Xenografts of EV and STK11 wildtype A549 cells
NSG mice were used as hosts for the flank injection of EV and STK11 50kD wildtype cell line variants of
A549 cells. Following tumor extraction, RNA was harvested and tested for changes in genes known to
be altered through STK11 loss in vivo. As expected, LINC00473 was extremely significantly elevated.
However, ODC1 expression was not significantly elevated (Log2 change of 0.25) (Figure 4.11). This data
suggests that xenograft models and the tumor microenvironment are not sufficient to induce the same
expression patterns seen in patient samples.

Figure 4.11 Xenografts do not restore patient phenotype of STK11 loss
A549 EV (blue) and 50kD STK11 WT (red) xenograft tumors harvested from NSG mice

c-KIT is a biomarker of STK11 loss in vivo
Biomarkers for STK11 loss are highly relevant, as only 50% of patients with STK11 loss are actually
detected through DNA sequencing alone (Chapter 2). Clinically, biopsy material is subjected to
measurement to aid diagnosis, prognosis, and to predict response to therapy. We first observed that cKIT expression was highly associated with STK11 loss through analysis of TCGA’s reverse phase protein
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array (RPPA) (Figure 4.12 A-B) with our signature for STK11 loss (p=1.14e-24). In validation of this result
we stained our tissue microarray of 150 patients (TMA150) with a c-KIT antibody and calculated percent
pixel positivity (Figure 4.12 C) (p=2.53e-10). KIT, or c-KIT, is a proto-oncogene and receptor tyrosine
kinase that has been shown to result in oncogenic growth upon its over-expression in melanoma, lung
cancer, and gastrointestinal cancers. A noteworthy observation is that KIT is most commonly associated
with GIST (Gastrointestinal stromal tumors) and activating mutations in KIT account for more than 85%
of all GIST tumors [180]. This is striking because STK11 germline mutations result in a condition known
as Peutz-Jeghers syndrome (PJS), a disease characterized by a predisposition for the development of
hamartomatous polyps in the gastrointestinal tract [50, 51]. Elevated both transcriptionally and
translationally, c-KIT is one of the best single clinical biomarkers for STK11 loss of function (Figure 4.12
A-B). It is uncertain whether or not c-KIT is functionally relevant in the context of STK11 deficient lung
adenocarcinoma but provides prognostic value in classification of patients and potentially response to
immunotherapy.
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Figure 4.12 KIT is a biomarker of STK11 loss
Discussion
In this study we transduced wildtype STK11 into cell lines with STK11 loss: A549, NCIH1437, and
NCIH1944. We describe that in vitro ODC1 expression is not altered through modulation of STK11
expression or through various conditions of metabolic stress. We discovered conferred resistance to
hypoxic response through cobalt chloride and sensitivity to interferon gamma as a result of STK11 loss.
STK11 loss was shown to increase glutamine sensitivity and consumption while hindering the utilization
of low concentrations of both glucose and glutamine. Finally, we conclude that KIT is a viable biomarker
of STK11 loss in vivo.
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A remarkable aspect of reconstitution of STK11 expression in mutant cell lines was how selective its
uptake was. Cell lines (NCIH: 1395, 2126) without a potent oncogenic driver such as KRAS or TP53 were
incapable of surviving STK11 addition. Both A549 and NCIH1944 contain mutations in STK11 and KRAS
while NCIH1437 has a mutation in both STK11 and TP53. Cell lines that managed to express STK11 and
survive had notable changes in their morphology as they were much more mesenchymal and elongated.
In addition to interferon gamma and cobalt chloride, we tested many other compounds for changes in
ODC1 expression and overall cell growth. Metformin (an activator of AMPK), resveratrol, protein kinase
C agonists (PKC) (upstream of STK11), 5-azacytidine (demethylating agent), dexamethasone, calcium and
potassium, glucose, atmospheric oxygen concentration, and essential amino acids had no impact on
ODC1 expression or cell viability with respect to STK11 status. These results further bring us to the
conclusion that in vitro cultures of STK11 loss undergo cell lineage differentiation that is no longer
comparable to in vivo patient tumor biology.
It is interesting that STK11 loss results in sensitivity to interferon gamma. Taken together with the lack
of immune infiltration seen in STK11 mutant patients and lack of response to immunotherapy, these
tumors could be extremely sensitive to the restoration of an anti-tumor immune response. Originally,
we hypothesized that methylation change and epigenetic silence could influence the expression of ODC1
expression. Treatment with 5-azacytidine had no impact on its expression (data not shown), suggesting
that this regulatory mechanism of gene expression is far more complex. In order to rule out the
possibility that other downstream pathways independent of STK11 could be contributing to ODC1
expression we treated cell lines with activators of PKC, AMPK, and CAMK. We also hypothesized that
ODC1 upregulation could be in response to diminished methionine levels that would otherwise be
restored through the methionine salvage pathway. Methionine deprivation alone had no impact on
ODC1 levels with respect to STK11 status. Finally, we tested whether amino acid catabolism and the
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urea cycle could be a result of a starvation response in the tumor as a result of decrease nutrient
availability. Serum, glucose, or amino acid deprivation in any combination did not result in the
restoration of the patient phenotype of ODC1 upregulation.
STK11 loss also impacted cellular growth and division at varying concentrations of glucose and
glutamine. At low concentrations A549 cells with STK11 loss grew as though there were no nutrients at
all while STK11 wildtype variants were able to slow cellular division in accordance to nutrient availability.
STK11 loss results in very polarized cell growth that may be advantageous above a certain threshold of
nutrient concentration but detrimental at ones below that. Given that patient tumors with STK11 loss
show upregulation of amino acid catabolism (Chapter 2) suggests that these tumors may be tapping into
starvation induced response while ignoring negative effects of slowed proliferation and apoptosis.
In conclusion, our attempts at studying the impact of STK11 loss on ODC1 function display the
limitations of in vitro work, especially in the context of metabolism. While STK11 loss spans many
biological functions and aids in tumor progression, certain aspects of STK11 loss appear to be specific to
cellular lineage (Chapter 3). Further studies should be performed from fresh patient tumor samples in
order to more accurately depict patient biology.
Materials and Methods
Molecular cloning
STK11
WT STK11 was ordered from Addgene (pcDNA3-FLAG-LKB1, Plasmid #8590) and constructs were made
for both 42kDa mutant and 50kDa WT isoforms. To produce the 42kDa mutant isoform of STK11, a
forward (GACTGGATCCGACGCC) and reverse (GGCCGCGAATTC) primer were used for PCR. The isolated
product was then sub-cloned into pENTR1A destination vector. The resulting plasmid was then
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recombined into pLenti-CMV-Puro and virus was produced. To produce the 50kDa WT STK11 isoform,
the WT sequence was sub-cloned into pENTR1a. This plasmid was then recombined into pLenti-CMVPuro and virus was produced.
ODC1
ODC1 ORF Vector (Human) (pORF) was ordered from abmgood (cat# ORF007352, lot#ML8154). The
ODC1 insert was sub-cloned into pENTR1A destination vector. This plasmid was recombined into pLentiCMV-Puro and virus was produced.
qPCR
For mRNA quantification, equal amounts of cDNA were synthesized from extracted total RNA samples
using a Bio-Rad iScript cDNA Synthesis Kit (1708890). The cDNA was combined with 2x PerfeCTa SYBR
Green SuperMix (Quantabio), respective forward and reverse primer, and loaded onto Bio-Rad
Multiplate PCR Plates (Cat. #MLL9601). 18S was amplified in each sample for loading control and
standardization.

qPCR Primers
Target
CX3CL1
GPT2
LINC00473
ODC1
18S

Forward Sequence
ACCACGGTGTGACGAAATG
TCCTTCCACTCCACCTCCAA
AGGCGGTTCCACCTTCTAAT
AGATCACCGGCGTAATCAAC
GTAACCCGTTGAACCCCATT

Reverse Sequence
TGTTGATAGTGGATGAGCAAAGC
TCAGGGTGCAGGTTGATCAC
CAGCTACTTGCCAACAACCA
CGGGCTCAGCTATGATTCTC
CCATCCAATCGGTAGTAGCG

IHC staining
Slides were stained using a Leica Bond RX automated system (Leica Biosytems, Buffalo Grove, IL) per the
manufacturer's protocol with proprietary reagents. Briefly, slides were deparaffinized on the automated
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system with Dewax Solution (Leica). Heat induced antigen retrieval was performed using Epitope
Retrieval Solution 2. The rabbit primary antibody that reacts to CD117 (#117R-14, Cell Marque, Rocklin,
CA) was used at a 1:100 concentration in Dako diluent (Carpenteria, CA) and incubated for 25 min. The
Leica Bond Polymer Refine Detection System was used. Post primary was incubated for 8 min. Polymer
was used for 8 min. Slides were then counterstained with Hematoxylin. Slides were dehydrated and
cover slipped per normal laboratory protocol.
Scoring of tissue microarray (TMA) slides was accomplished by using Leica Biosystems Aperio eSlide
Manager online software. Each core of the TMA was segmented and used to calculate percentage of
positive pixels for the respective stain, as we have previously described [116].
Interferon gamma and cobalt chloride
Interferon gamma was ordered from Thermo Scientific (Lot #SK2477231) and diluted in tissue culture
purified water to a concentration of 100µg/mL. Cells were treated with various concentrations of
interferon gamma in a 96 well plate. Cobalt chloride was ordered from MP Biomedicals, LLC
(CAS #7791-13-1) and diluted in tissue culture purified water to a concentration of 100mM.
Tissue culture and cell lines
The following cell lines were acquired from the Moffitt Cancer Center cell line repository: A549,
NCIH1437, and NCIH1944. Cells were grown in standard RPMI with 10% fetal bovine serum (FBS) unless
amino acid or glucose levels were altered in which case dialysed FBS (dFBS) was used in order to avoid
supplementing the nutrients we were removing. Cells were grown in a tissue culture incubator at 5%
CO2 for the allotted time points.
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Seahorse assays
The seahorse XF96 analyzer was used for this experiment (https://www.agilent.com/en/products/cellanalysis/seahorse-analyzers/seahorse-xfe96-analyzer). A549 cells were plated at a density of 5,000 cells
per well of seahorse XF 96 well cell culture microplate and allowed to adhere overnight for 24 hours.
Seahorse XF calibrant solution was added to each well of the 96 well sensor cartridge and placed in a
non CO2 incubator overnight. One hour prior to the experiment, the media was replaced with Seahorse
XF RPMI medium and injection ports were loaded at a 10x concentration. Seahorse Wave software was
used for the analysis of the results.
Celigo image analysis
The Celigo imaging cytometer (https://www.nexcelom.com/nexcelom-products/cellometer-and-celigoimage-cytometers/celigo-imaging-cytometer/) was used to count cells stained with a final concentration
of 1uM Hoechst. Cells were plated at a concentration of 5,000 cells per well of a 96 well plate.
RNA extraction
For harvesting, cells were trypsinized, spun down for 5 minutes at 1,500 RPM (4˚C), and resuspended in
RLT Buffer (Qiagen, Lot #160019989) supplemented with β-mercaptoethanol (Sigma-Aldrich, Lot
#79296HMV). A Qiagen RNeasy Mini Kit (Cat. #74104) was used for total RNA extraction.
Protein extraction
A cell scraper was used to harvest cells. The cells were spun down for 5 minutes at 1,500 RPM (4˚C) to
make cell pellet. A total protein lysate was extracted by resuspending cell pellet in RIPA Buffer
(Cell Biolabs, INC. AKR-191) + Protease and Phosphatase Inhibitor Cocktail (Sigma-Aldrich, Lot#
117M4185V), incubated on ice for 20 minutes and vortexed 4-5 times regularly, and centrifuged for 20
minutes at 14,000 RPM (4˚C).
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Chapter 5: Transcriptional, proteomic and metabolic characterization of lung adenocarcinoma

Abstract
Lung adenocarcinoma is the most common histological subtype of lung cancers. In this study, we
characterize a cohort of 123 lung adenocarcinoma patients. We associate gender, smoking, survival and
common driver mutations (EGFR, KEAP1, KRAS, STK11, and TP53) with comprehensive gene expression,
proteomic and metabolic measurements. Additionally, we classify patients based on interferon and
inflammatory signaling and further characterize these cohorts. From the metabolite, protein, and gene
expression datasets we used principal component analysis (PCA) to transform the data into the top ten
components and assessed these transformations in each of the predefined cohorts. These components
were described using Gene Set Enrichment Analysis (GSEA) for both mRNAs and proteins and a Python
based metabolic pipeline (mummichog) for metabolites. There were significant relationships between
genetic drivers, immune signatures, and our generated components. This study uncovers novel
molecular associations between multi-dimensional molecular data with the potential for hypotheses
that could ultimately lead to targeted therapeutic interventions. One of the most fascinating discoveries
in this study is uniqueness of EGFR mutations compared to others. Patients with EGFR mutations had
significantly increased frequency in female gender over male, better prognosis, and were metabolically
characterized by histidine metabolism and histamine production. Furthermore, heightened
inflammatory response predicted from gene expression was significantly enriched for pyrimidine
metabolism and displayed elevated levels of pyridine-2,3-dicarboxylate, nicotinate, kynurenine, and
putrescine. We conclude this study by generating prognostic signatures from the metabolomics and
proteomics dataset.
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Introduction
Constitutive activation or amplification of oncogenes KRAS and EGFR are a hallmark of lung
adenocarcinoma [181-183], while deletions and inactivation of tumors suppressors TP53, STK11, and
KEAP1 are also commonly seen [10, 184-186]. A majority of patient tumors has at least one of these
genetic abnormalities, while others either have no identifiable genetic abnormality or ones that are far
less common such as: FRAS, BRAF, ALK, BRG1, CDKN2A and others. Up until now, the most
comprehensive analysis of these genes corresponding to tumor initiation and progression has involved
changes in gene expression through measurement of the abundance of mRNA transcripts. Other studies
such as TCGA have constructed cohorts of various tumor histology that contain a myriad of genetic
information such as next generation DNA and RNA sequencing, copy number, methylation, and protein
data. While these studies have pioneered the field of multi-omics characterization, they have several
limitations including: limited protein information (<300) through utilization of reverse phase protein
arrays and a lack of metabolomics.
We have previously described a cohort of approximately 150 lung adenocarcinoma patients (referred to
as MLCom [116, 139], Moffitt Lung Complete) that includes clinical metadata, limited protein[116, 187,
188] and LINC00473[129] expression data derived from a tissue microarray, driver mutation data in the
form of Sanger sequencing and Affymetrix-based gene expression data [116, 126, 129, 139, 140, 187189]. Herein, we expand 123 patients of this cohort to also contain 6285 metabolite features and 5834
proteins through use of liquid chromatography mass spectrometry (LS-MC). This unique cohort allows
for the multi-omics analysis of gene expression, protein, and metabolite in the context of DNA
mutations of TP53, KRAS, EGFR, and STK11 identified through Sanger sequencing. Additionally,
alterations in STK11 and KEAP1 are much more accurately identified through gene expression
signatures, which we will use in this study. To our knowledge, this is the largest cohort of lung
adenocarcinoma that has been extensively profiled using LC-MS for proteins and identified metabolite
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features. In this study we extend our understanding of lung adenocarcinoma through the analysis of
gene expression, protein, and metabolite data with comprehensive and integrated analysis of DNA
mutations, gender, smoking and overall survival. Using these methods, we detect novel proteins and
metabolites associated with both genetic background and immune surveillance.
Results
Description of the dataset
Clinical data
Of the 123 patients, there were only 9 (7.32%) that reported to have never smoked while 94 (76.42%)
had a history of prior smoking. Gender was equally represented with 62 (50.40%) males and 61
(49.60%) females. Most tumors were early staged by pathology: stage 1 (52.03%), stage 2(17.07%),
stage 3 (16.26%), stage 4 (5.69%), and unknown (8.94%). Sanger sequencing identified the following
mutations: KRAS (43.08%), TP53 (33.33%), STK11 (28.45%), and EGFR (9.75%). Only 13 patients (10.57%)
had no identifiable driver mutation. Through gene expression signature there were 51 (41.46%) patients
with predicted STK11 and 38 (30.89%) with KEAP1 mutation (Figure 5.1A). The median follow-up time
was 31.1 months of the 80 patients alive at the time of the last follow up, 40 patients had died with a
median survival of 16.8 months.
Metabolome
Using LC-MS, 6285 metabolite features were extracted, 3151 as negative ions and 3134 as positive ions.
Of these, 259 metabolite features were identified from our annotated library with 193 unique
metabolites; the remaining 6026 features were analyzed as mass to charge (m/z) ratios (Figure 5.1B).
Proteome
Through LC-MS, we profiled 5834 proteins (Figure 5.1C). Of the 5834 proteins, 2533 (43.4%) had 75100% coverage, 925 (15.6%) had 50-75% coverage, 1128 (19.3%) had 25-50% coverage, and 1247
(21.3%) had 0-25% coverage (Figure 5.1D). Total coverage was seen for 831 proteins (14.2%).
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Figure 5.1 The MLOS cohort of 123 patients with gene, protein and metabolite data
(a) Explanation of the information available in the cohort with provided mutational frequencies (b)
Metabolite peak height and variation across 6285 features (c) Protein expression and variation across
5824 proteins (d) Coverage of proteins separated into bins by 10%
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Clinical associations by mutation
By gender, EGFR mutations were considerably more likely to be female (82.35%) than male (17.65%,
p=0.0061). On the other hand, both STK11 mutations were enriched in males (66.66%) compared to
females (33.34%, p=0.02, Figure 5.2A). Mutational co-occurrence displayed that KEAP1 and STK11
mutations were commonly found in the same patient (Figure 5.2B). EGFR mutations had the highest
rate of co-occurring TP53 mutation while STK11 and KEAP1 were more likely to be TP53 wild type.
Analysis of smoking status by mutation revealed an increased rate of EGFR mutations amongst nonsmokers (29.41%, p=1.0e-4), with no significant variation between the other characterized mutations
(70-86%, Figure 5.2C). There was a significantly better prognosis amongst patients who had an EGFR
mutation compared to any other (p = 0.22, Figure 5.2D).

Figure 5.2 Clinical features with respect to mutational frequency
(a) Gender frequency by mutation (b) Mutational co-occurrence (c) Smoking history by mutation (d)
Overall survival at 3 years by mutation
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Molecular characterization by mutation
In the sections that follow, each mutation whether identified through sequencing (EGFR, KRAS, and
TP53) or gene expression signature (STK11 and KEAP1) was characterized by changes in gene expression,
protein expression, and metabolite abundance. The top 150 unique genes or proteins that changed the
most were then enriched against MSigDB’s hallmark geneset while mummichog[190] was used to
identify enriched metabolic pathways. Results of each analysis are tabulated, with gene set enrichment
annotated by rank and metabolite by pathway associated p-value.
TP53
TP53 had the least significant changes to gene expression among the five mutations by p-value despite
the large percentage of TP53 mutations in the cohort. Top gene sets by gene expression included: E2F
targets (FDR = 4.16e-56) and G2M checkpoints (FDR = 2.15e-54) (Table 5.1). Proteins followed a similar
pattern as gene expression as there was very minimal significance to their expression patterns. Top
changing proteins were enriched for E2F targets (FDR = 8.66e-8) and hypoxia (FDR = 7.18e-7) (Table 5.2).
Metabolites were enriched in the pathways for the carnitine shuttle (p = 0.00011), fatty acid activation
(p = 0.00576), and de novo fatty acid biosynthesis (p = 0.00938) (Table 5.3).
EGFR
EGFR had no significant gene sets that were enriched amongst its most significantly altered genes (Table
5.1). By protein, expression fatty acid metabolism (FDR = 2.7e-6), complement pathway (FDR = 1.06e-4),
and coagulation (1.06e-4) were amongst the most enriched (Table 5.2). Notable changing proteins
include a decrease in DSG2, NAMPT, CFL1, GOT1, and NNMT. There was a significant increase in the
proteins CTSH, ACAD8, and class II HLA molecules (DRA and DPA1) (Table 5.4A). Metabolically EGFR
mutations were strongly associated with the TCA cycle (p = 0.105), histidine metabolism (p = 0.117),
lysine metabolism (p = 0.0178), and caffeine metabolism (p = 0.0178) (Table 5.3). Altered metabolites
include an increase in l-carnitine, pyridoxine, propionate, and histamine (Table 5.4B)
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KRAS
KRAS had a lower level of statistical significance to gene expression changes by raw p-value with most
altered genes in the range of greater than 1e-10. Top gene sets include coagulation (FDR = 3.69e-2) and
apical junction (FDR = 3.69e-2) (Table 5.1). By protein, apical junction was also enriched (FDR = 2.91e-3)
and separately cholesterol homeostasis (FDR = 2.91e-3) (Table 5.2). Metabolically, KRAS status was
associated with arginine and proline metabolism (p = 0.128), n-glycan biosynthesis (p = 0.020), heparin
sulfate degradation (p = 0.025), and glyocosphingolipid biosynthesis (p = 0.049) (Table 5.3). Due to the
low significance of molecular characteristics we did not include them in a table.
STK11
STK11 had very strong gene, protein, and metabolite signatures. By gene set enrichment, inflammatory
response was the most significantly altered pathway (FDR = 1.04e-9) followed by early estrogen
response (FDR = 3.65e-5) (Table 5.1). Protein expression changes were enriched for xenobiotic
metabolism (FDR = 7.9e-14) and interferon gamma response (FDR = 4.78e-11) (Table 5.2). Noteworthy
increasing proteins include ASAH1, PGC, CPS1, ANXA1, and SFTPB (Table 5.5A). Metabolite enrichment
revealed a significant alteration in the carnitine shuttle (p = 0.002), fatty acid metabolism (p = 0.025),
glycosphingolipid metabolism (0.037), and arginine and proline metabolism (p = 0.044) (Table 5.3).
Metabolites increased as a result of STK11 loss include increases in ethylmalonic acid, n-acetyl-GABA,
putrescine, GABA and n-acetyl putrescine (Table 5.5B).
KEAP1
KEAP1 had the strongest gene and protein expression patterns. Gene expression enrichment revealed
changes to xenobiotic metabolism (FDR = 2.38e-16) and the reactive oxygen species pathway (FDR =
1.14e-14) (Table 5.1). Proteins were enriched for the exact same pathways: xenobiotic metabolism (FDR
= 7.39e-21) and the reactive oxygen species pathway (1.64e-18) (Table 5.2). Notable increases in
proteins include AKR1C1 and 2, UGDH, NQO1, and G6PD (Table 5.6A). Metabolites shows the most
drastic changes to aspartate and asparagine metabolism (p = 0.069) and glutathione metabolism (p =
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0.062) (Table 5.3). Given that nearly 80% of patients with a KEAP1 mutation also have STK11 loss, there
is a notable increase in STK11 related metabolites. Taking this into consideration, there is an increase in
hypotaurine and taurine and a decrease in creatine levels (Table 5.6B).
Table 5.1 - Gene set enrichment of Hallmarks by Mutation
Pathways

EGFR

KEAP1

KRAS

STK11

TP53

Xenobiotic Metabolism

-

1

-

-

-

Reactive Oxygen Species

-

2

-

-

-

Fatty Acid Metabolism

-

3

-

-

-

MTOR Signaling

-

4

-

-

-

Glycolysis

-

5

-

-

-

Coagulation

-

-

1

-

-

Apical Junction

-

-

2

-

-

Myogenesis

-

-

3

-

-

TNFa signaling via NFKB

-

-

4

-

-

Inflammatory Reponse

-

-

-

1

-

Estrogen Response Early

-

-

-

2

-

IL2 STAT5 Signaling

-

-

-

3

-

Estrogen Response Late

-

-

-

4

-

Interferon Gamma Response

-

-

-

5

-

E2F Targets

-

-

-

-

1

G2M Checkpoint

-

-

-

-

2

Mitotic Spindle

-

-

-

-

3

MYC Targets

-

-

-

-

4

Spermatogenesis

-

-

-

-

5

Table 5.2 - Protein set enrichment of Hallmarks by Mutation
Pathways

EGFR

KEAP1

KRAS

STK11

TP53

Fatty Acid Metabolism

1

3

3

3

-

Complement

2

-

-

-

-

Coagulation

3

-

-

-

-

Heme Metabolism

4

-

-

-

-
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MTOR Signaling

5

4

-

4

4

Xenobiotic Metabolism

-

1

-

1

-

Reactive Oxygen Species

-

2

-

-

-

Glycolysis

-

5

-

-

3

Apical Junction

-

-

1

-

-

Cholesterol Homeostasis

-

-

2

-

-

Protein Secretion

-

-

4

-

-

Unfolded Protein Response

-

-

5

-

-

Interferon Gamma Response

-

-

-

2

-

Interferon Alpha Response

-

-

-

5

-

E2F Targets

-

-

-

-

1

Table 5.3 - Metabolic pathway enrichment by Mutation
Pathways
TCA cycle
Histidine metabolism
Caffeine metabolism
Lysine metabolism
Arginine and Proline Metabolism
Ascorbate and Aldarate Metabolism
N-Glycan Degradation
Prostaglandin formation
Fatty acid activation
De novo fatty acid biosynthesis
Carnitine shuttle
Glycosphingolipid biosynthesis
Aspartate and asparagine metabolism
Chondroitin sulfate degradation
Heparan sulfate degradation
N-Glycan biosynthesis
Glycosphingolipid metabolism
Glutathione Metabolism

EGFR
0.010547
0.011656
0.017714
0.017876
0.064527
0.091962
0.162159
0.162159
0.220325
0.239734
0.414751
0.461507
0.601609
0.816377
0.816377
0.893793
0.914322
1

KEAP1
0.350359
0.953568
0.57737
0.522299
0.276891
0.71747
0.058939
0.058939
0.559385
0.963917
0.580907
0.310984
0.069876
0.228423
0.228423
0.182565
0.645735
0.061886

KRAS
0.920227
0.993766
0.391382
0.124584
0.012836
0.683127
0.128265
0.128265
0.544902
0.517662
0.72206
0.049598
0.141304
0.024698
0.024698
0.020323
0.353905
0.938117

STK11
0.852334
0.777195
1
0.579914
0.044627
1
0.081248
0.308533
0.024852
0.178018
0.002084
0.579019
0.15978
0.308533
0.308533
0.764047
0.037157
0.333762

TP53
0.77431
0.959729
0.922912
0.76307
0.24803
0.059395
0.406833
1
0.005764
0.009384
0.000106
0.922912
0.442367
0.131982
0.131982
0.972508
0.366433
0.747941

Log 2 change
-2.02
-1.64
1.66

p-value
2.55E-07
2.50E-06
3.73E-06

Table 5.4A - Top 20 EGFR related proteins by p-value
Protein
DSG2
NAMPT
CTSH

Description
desmoglein 2
nicotinamide phosphoribosyltransferase
cathepsin H
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CFL1
ACAD8
EEF1B2
HLA-DRA
BCCIP
GOT1
EEF1G
MAPK8IP3 SPAG9
PPA1
NARS
NNMT
HLA-DPA1
HSD17B8
PGM3
ASNS
ZC3HC1
NME1

cofilin 1 (non-muscle)
acyl-CoA dehydrogenase family member 8
eukaryotic translation elongation factor 1 beta 2
major histocompatibility complex, class II, DR alpha
BRCA2 and CDKN1A interacting protein
glutamic-oxaloacetic transaminase 1, soluble
eukaryotic translation elongation factor 1 gamma
pyrophosphatase (inorganic) 1
asparaginyl-tRNA synthetase
nicotinamide N-methyltransferase
major histocompatibility complex, class II, DP alpha
1
hydroxysteroid (17-beta) dehydrogenase 8
phosphoglucomutase 3
asparagine synthetase (glutamine-hydrolyzing)
zinc finger, C3HC-type containing 1
NME/NM23 nucleoside diphosphate kinase 1

-0.62
1.95
-1.03
1.59
-1.50
-0.85
-0.87
1.00
-0.69
-0.78
-1.52

9.43E-06
1.17E-05
1.77E-05
2.48E-05
3.32E-05
3.47E-05
3.63E-05
4.30E-05
4.40E-05
5.13E-05
6.42E-05

1.69

6.78E-05

1.51
-1.09
-2.07
2.25
-0.94

8.03E-05
8.71E-05
8.91E-05
9.97E-05
0.000105

Table 5.4B - Top 10 EGFR related annotated metabolites by p-value
Metabolite
L-CARNITINE
PYRIDOXINE
PROPIONATE
PUTRESCINE
BENZYLAMINE
HISTAMINE
D-FRUCTOSE
GLYOXYLIC ACID
D-SACCHARIC ACID;GALACTARATE
3-HYDROXYBENZYL ALCOHOL

Log2 change
0.95
1.55
1.02
-1.41
1.41
2.31
0.99
1.19
1.15
-0.07

p-value
5.19E-06
2.32E-05
2.43E-05
5.23E-05
5.44E-05
8.16E-05
0.000277
0.000563
0.000658
0.000663

Table 5.5A - Top 20 STK11 related proteins
Protein
ASAH1
AKR1C1

Description
N-acylsphingosine amidohydrolase (acid ceramidase) 1
aldo-keto reductase family 1, member C1
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Change
1.19
2.70

p-value
1.44E-08
5.54E-08

PIR
AKR1C2
FASN DCXR-DT
DPYD
PPP1R18
CPS1
NAXE
ANXA1
PGC
GORASP2
S100P
COTL1
ACADVL
UGDH
PSMB9
AKR1D1
TACC2
SFTPB

pirin
aldo-keto reductase family 1, member C2
dihydropyrimidine dehydrogenase
protein phosphatase 1 regulatory subunit 18
carbamoyl-phosphate synthase 1
apolipoprotein A-I-Binding Protein
annexin A1
progastricsin (pepsinogen C)
golgi reassembly stacking protein 2
S100 calcium binding protein P
coactosin-like F-actin binding protein 1
acyl-CoA dehydrogenase, very long chain
UDP-glucose 6-dehydrogenase
proteasome subunit beta 9
aldo-keto reductase family 1, member D1
transforming, acidic coiled-coil containing protein 2
surfactant protein B

2.10
3.12
1.23
-1.25
-0.98
2.13
0.86
-1.01
3.96
0.83
2.34
-0.94
0.88
1.15
-0.76
2.14
1.23
2.16

4.95E-07
7.78E-07
7.93E-07
1.21E-06
1.26E-06
3.36E-06
4.48E-06
4.61E-06
5.31E-06
6.50E-06
6.66E-06
6.82E-06
9.20E-06
1.04E-05
1.30E-05
1.41E-05
1.45E-05
1.47E-05

Log2 change
4.55
5.36

p-value
2.59E-22
2.75E-19

Table 5.5B - Top 10 STK11 related annotated metabolites
Metabolite
ETHYLMALONIC ACID
4-ACETAMIDOBUTANOATE
4-ACETAMIDOBUTANOATE
PUTRESCINE
4-AMINOBUTANOATE
N-ACETYLPUTRESCINE
URIDINE
URIDINE
2,6-DIHYDROXYPYRIDINE
PALMITATE

Log2 change
1.00
1.12
0.95
1.19
0.85
1.12
0.66
0.60
0.49
0.49

p-value
4.87E-08
3.13E-07
5.65E-07
6.90E-07
2.11E-06
3.33E-05
9.02E-05
0.00013
0.00017
0.000263

Table 5.6A - Top 20 KEAP1 related proteins
Protein
AKR1C1
AKR1C2

Description
aldo-keto reductase family 1, member C1
aldo-keto reductase family 1, member C2
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UGDH
AKR1D1
NQO1
CBR1
G6PD
GCLC
TXNRD1
ALDH3A1
TALDO1
AKR1B10
PIR
ME1
--PPP1R18
FASN DCXR-DT
IDH1
AKR1C3
VAPA

UDP-glucose 6-dehydrogenase
aldo-keto reductase family 1, member D1
NAD(P)H dehydrogenase, quinone 1
carbonyl reductase 1
glucose-6-phosphate dehydrogenase
glutamate-cysteine ligase, catalytic subunit
thioredoxin reductase 1
aldehyde dehydrogenase 3 family member A1
transaldolase 1
aldo-keto reductase family 1, member B10
pirin
malic enzyme 1, NADP(+)-dependent, cytosolic
protein phosphatase 1 regulatory subunit 18
isocitrate dehydrogenase 1 (NADP+)
aldo-keto reductase family 1, member C3
VAMP associated protein A

2.15
3.78
3.49
1.97
1.69
2.20
1.86
4.13
0.81
4.52
2.60
1.48
2.26
-1.17
1.44
0.71
2.45
1.10

6.19E-18
1.30E-16
1.54E-13
1.22E-12
1.30E-11
1.73E-11
2.32E-11
2.39E-10
3.23E-10
8.19E-10
8.40E-10
9.32E-09
1.20E-08
2.82E-08
3.97E-08
6.41E-08
7.72E-08
1.05E-07

Table 5.6B - Top 10 KEAP1 related annotated metabolites
Metabolite
HYPOTAURINE
4-ACETAMIDOBUTANOATE
HYPOTAURINE
PUTRESCINE
4-ACETAMIDOBUTANOATE
4-METHYL-2-OXOVALERIC ACID
ETHYLMALONIC ACID
3-METHYL-2-OXOVALERIC ACID
TAURINE
CREATINE

Log2 change
0.75
0.86
0.70
0.89
0.69
0.94
0.64
0.69
0.24
-0.49

p-value
4.96E-05
0.000361
0.000579
0.000674
0.000825
0.001009
0.001603
0.003869
0.00503
0.018545

Immune Signatures
We used gene sets describing immune related signaling from MSigDB’s hallmark geneset. Both
inflammatory response and interferon gamma response gene sets contained 200 genes, with only 37
genes overlapping between each pathway.
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Interferon Gamma response
Patients were clustered by gene expression into two distinct populations representing extremes of
expression: interferon gamma low (n = 52) and high (n = 71) (Figure 5.3A). Patients were further
analyzed for changes in metabolite and protein abundance. As expected proteins were enriched in
interferon gamma (FDR = 2.09e-16) and alpha (FDR = 1.95e-12) response (data not shown). There was
an increase in STAT1, GBP1 and 2, and PYCARD with a decrease in ALDH3A1 and AKR1C1 protein
expression (Table 5.7A). Butanoate metabolism (p = 0.0017) was the leading altered metabolic pathway
(Table 5.9). Followed by: lysine (p = 0.0035), tryptophan (p = 0.0176), and aspartate and asparagine (p =
0.025) metabolism. Interestingly, there was a significant increase in pyridine-2,3-dicarboxylate,
nicotinate, kynurenine and betaine in patients with high interferon response (Table 5.7B).

Table 5.7A - Top 20 proteins as a result of interferon gamma signaling high vs low
Protein
GBP1
HSPA1A HSPA1B
GBP2
STAT1
PYCARD

Description
guanylate binding protein 1, interferon-inducible
heat shock protein family A/B (Hsp70) member 1A/B
guanylate binding protein 2, interferon-inducible
signal transducer and activator of transcription 1
PYD and CARD domain containing
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Log2 Change
1.73
-0.56
1.41
1.34
0.98

p-value
2E-09
6.08E-08
9.2E-08
1.21E-07
7.59E-07

LAP3
EFHD2
PSME2
CBR1
ALDH3A1
WARS
PSMB9
SAMHD1
AKR1C1
CASP1
ALDH6A1
PSME1
AKR1C2
LCP1
PTRHD1

leucine aminopeptidase 3
EF-hand domain family member D2
proteasome activator subunit 2
carbonyl reductase 1
aldehyde dehydrogenase 3 family member A1
tryptophanyl-tRNA synthetase
proteasome subunit beta 9
SAM domain and HD domain 1
aldo-keto reductase family 1, member C1
caspase 1
aldehyde dehydrogenase 6 family member A1
proteasome activator subunit 1
aldo-keto reductase family 1, member C2
lymphocyte cytosolic protein 1 (L-plastin)
peptidyl-tRNA hydrolase domain containing 1

0.64
0.98
0.93
-1.29
-2.90
0.84
0.79
0.84
-2.25
1.01
-1.23
0.61
-2.81
0.83
-0.78

Table 5.7B - Top 14 metabolites as a result of interferon gamma signaling high vs low
Metabolite
PYRIDINE-2,3-DICARBOXYLATE
NICOTINATE
DL-KYNURENINE
BETAINE
TRANS-4-HYDROXYPROLINE
5,6-DIHYDROURACIL
3-HYDROXY-3-METHYLGLUTARATE
DEOXYCARNITINE
URACIL
SPHINGANINE
N(PAI)-METHYL-L-HISTIDINE
XANTHOSINE
L-GLUTAMIC ACID
THIAMINE

Log2 change
2.64
1.36
1.39
0.55
0.43
0.59
0.36
0.79
0.62
0.33
0.39
0.43
0.36
0.38
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p-value
6.30E-08
7.57E-07
6.05E-05
0.002089
0.003047
0.003083
0.003874
0.004679
0.00545
0.008811
0.009837
0.010345
0.012294
0.012406

9.07E-07
9.86E-07
1.78E-06
2.45E-06
3.96E-06
4.82E-06
6.47E-06
7.79E-06
8.37E-06
9.23E-06
9.27E-06
1.11E-05
1.16E-05
1.89E-05
1.98E-05

Figure 5.3 Characterization and prognosis of immune signatures
(a) Clustering of patients into interferon low (n = 52) (left) and high (n = 71) (right) (b) Clustering of
patients into inflammatory low (n = 25) (left) mid (n = 47) (middle) and high (n = 45) (right) (c) Overall
survival at 3 years for each of the 5 clusters mentioned previously
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Inflammatory Response
Likewise, the hallmark gene set for inflammatory response was also used to cluster patients. This time,
patients were clustered into 3 distinct populations: inflammatory low (n = 25), middle (n = 47), and high
(n = 51) (Figure 5.3B). Enrichment was further run on the proteins and metabolites altered between low
and high subsets. Hallmarks for proteins were again enriched in interferon gamma (FDR = 1.24e-12) and
alpha pathways (FDR = 1.16e-9). Protein expression changes were very similar to interferon gamma
response (Table 5.8A). Mummichog analysis of metabolites resulted in enrichment of pyrimidine
metabolism (p = 0.0035), aspartate and asparagine metabolism (p = 0.064), and the urea cycle (p =
0.067) (Table 5.9). Many metabolites were changing similarly to interferon gamma response with key
exceptions being a decrease in both putrescine and GABA (Table 5.8B). Histamine and d-ornithine were
also seen to be increased in patients with high levels of inflammation.
Prognostic significance of immune signatures
Surprisingly, amongst the two signatures for interferon response, low interferon signaling had a slightly
better prognosis than high although not significant (p = 0.44) (Figure 5.3C). Inflammatory signaling had
a significant increase in survival amongst the patients who clustered in the “middle” cohort (p < 0.006)
while both low and high inflammatory signaling resulted in a poor prognosis (Figure 5.3C).
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Table 5.8A - Top 20 proteins as a result of inflammatory signaling high vs low
Protein
SAMHD1
PSMB9
GBP1
AKR1C2
PPP1R18
GBP2
COTL1
AKR1C1
SERPINB9
LSP1
RAC2
ARHGAP25
EFHD2
OPTN
PYCARD
CORO1A
AKR1D1
LAP3
HSPA1A HSPA1B
ALDH3A1

Description
SAM domain and HD domain 1
proteasome subunit beta 9
guanylate binding protein 1, interferon-inducible
aldo-keto reductase family 1, member C2
protein phosphatase 1 regulatory subunit 18
guanylate binding protein 2, interferon-inducible
coactosin-like F-actin binding protein 1
aldo-keto reductase family 1, member C1
serpin peptidase inhibitor, clade B, member 9
lymphocyte-specific protein 1
ras-related C3 botulinum toxin substrate 2
Rho GTPase activating protein 25
EF-hand domain family member D2
optineurin
PYD and CARD domain containing
coronin, actin binding protein, 1A
aldo-keto reductase family 1, member D1
leucine aminopeptidase 3
heat shock protein family A/B (Hsp70) member 1A/B
aldehyde dehydrogenase 3 family member A1

Log2 change
1.54
1.44
2.30
-4.81
1.57
1.88
1.48
-3.66
1.19
1.45
1.62
1.63
1.37
1.60
1.36
1.34
-3.20
0.90
-0.70
-3.88

Table 5.8B - Top 14 metabolites as a result of inflammatory signaling high vs low
Metabolite
PYRIDINE-2,3-DICARBOXYLATE
NICOTINATE
DL-KYNURENINE
PUTRESCINE
ETHYLMALONIC ACID
BETAINE
4-AMINOBUTANOATE
TRANS-4-HYDROXYPROLINE
DEOXYCARNITINE
L-ASPARAGINE
N-ACETYLPUTRESCINE
L-GLUTAMIC ACID
HISTAMINE
URACIL

Log2 change
2.64
1.36
1.37
-1.18
-0.77
0.55
-0.68
0.43
0.79
0.46
-0.95
0.36
1.26
0.62
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p-value
3.54E-07
6.98E-05
0.000568
0.00058
0.007168
0.00895
0.009208
0.010195
0.013385
0.015596
0.01624
0.018254
0.021956
0.026331

p-value
1.85E-08
2.29E-08
8.54E-08
8.73E-08
1.06E-07
1.18E-07
1.31E-07
3.02E-07
5.86E-07
7.02E-07
8.33E-07
8.51E-07
2.22E-06
2.26E-06
2.46E-06
2.52E-06
2.67E-06
2.67E-06
2.90E-06
3.09E-06

Table 5.9 - Metabolic pathways enriched through immune signatures
Pathway
Arginine and Proline Metabolism
Aspartate and asparagine metabolism
Butanoate metabolism
Chondroitin sulfate degradation
Glutathione Metabolism
Heparan sulfate degradation
Lysine metabolism
Purine metabolism
Pyrimidine metabolism
Tryptophan metabolism
Urea cycle/amino group metabolism

IFNG
0.048
0.025
0.002
0.043
0.041
0.043
0.003
0.596
0.042
0.018
0.458

Inflammatory
0.157
0.064
0.556
0.479
0.769
0.479
0.125
0.070
0.034
0.138
0.066

Decomposition of metabolites, proteins, and gene expression
To reduce the complexity of these datasets we utilized principal component analysis on the
metabolomics, proteomics, and gene expression matrices. Each dataset was reduced to the top 10
principal components, which were further used to relate changes of each series of molecular data to
one other. Average principal component scores for each dataset were calculated between the
molecular subtypes mentioned above. By gene expression, EGFR had a low expression of signature 1 and
6. STK11 mutation was described through signature 6, and KEAP1 through signature 3 and 4 (Figure
5.4A). KRAS and TP53 were not described well through the top 10 principal components by gene
expression, as might be expected from the results of Table 5.1. The protein components also described
a variety of mutations. EGFR had low signature 1 and 5, STK11 was high for signature 5, and KEAP1 was
described through signature 3 (Figure 5.4B). KRAS was described through a reduction in signature 2
while signature 1 and 4 described TP5 status partially. Metabolites were not as descriptive through
principal component decomposition with component 1 and 2 describing EGFR mutations and STK11
mutations partially (Figure 5.4C). Gene expression component 2 accurately described both
inflammation and interferon gamma response (Figure 5.4 A-B). A variety of protein signatures were
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altered by these same clusters (Figure 5.5 C-D). Metabolic signatures 1 and 2 partially explained the
inflammatory signaling (Figure 5.5E), while none sufficiently described interferon response (Figure 5.5F).
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Figure 5.4 Component scores by mutation
(a-c) Component scores by mutation for genes (a), proteins (b), and metabolites (c)

130

Figure 5.5 Component scores by immune signature

(a-f) Component scores of genes (a-b), proteins (c-d), and metabolites (e-f) for both the
inflammatory response clusters (a,c,e) and interferon gamma response clusters (b,d,f)
Relationship and identification of components
The top components were classified through gene set enrichment for both proteins and genes while
metabolites were analyzed through mummichog. The top 75 proteins and 300 genes by absolute
principal component coefficients were analyzed for enrichment to the hallmark gene set used earlier
(Table 5.10 and 11). Metabolites were analyzed in a manner corresponding to their principal
component score for pathway analysis (Table 5.12). The correlation matrix of the top 10 principal
components of each dataset helps simplify the complex relationship between them (Figure 5.6A). The
strongest connectivity between components was seen between proteins and metabolites followed by
genes and proteins. The smallest correlations were seen between genes and metabolites. The most
related gene components were component 1 with protein component 1 and gene component 8 with
metabolite component 9. Protein component 1 was highly associated with metabolite component 2.
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Table 5.10 - Gene set enrichment of principal components
Pathways
E2F TARGETS
G2M CHECKPOINT
MITOTIC SPINDLE
MYC TARGETS
MTORC1 SIGNALING
ALLOGRAFT REJECTION
EPITHELIAL MESENCHYMAL
TRANSINSITION
INFLAMMATORY RESPONSE
COMPLEMENT
INTERFERON GAMMA
RESPONSE
TGF BETA SIGNALING
PROTEIN SECRETION
P53 PATHWAY
APICAL JUNCTION
KRAS SIGNALING
TNFA SIGNALING VIA NFKB
UV RESPONSE
APOPTOSIS
XENOBIOTIC METABOLISM

PC1

PC2

PC3

PC4

PC5

PC6

PC7

PC8

PC9

1
2
3
4
5
-

1

5
1
2
-

3
2
1
4
-

1
-

1

1

4
-

2
5
4
1
-

PC1
0
2
1
3
-

-

2

-

-

-

-

3

-

-

-

-

3
4

-

-

-

2
-

4
-

-

-

-

-

5

-

-

-

4

2

-

-

-

-

-

3
4
-

-

2
-

3
5
-

4
5
5
-

1
3
5
2

-

-
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Table 5.11 - Protein set enrichment
PC_
2

Coagulation

PC_
1
1

Complement

2

4

MYC Targets

3

1

Heme Metabolism

4

Xenobiotic Metabolism

5

Pathways

PC_
3

PC_
4

PC_
5
2

2

MTOR Signaling
Epithelial Mesinchymal
Transition
Adipogenesis

3

PC_
7

PC_
8

PC_
9

PC_1
0

4
3

1

4

Glycolysis

PC_
6

1

1

1

2

4

5

3

5

1

4

5

2

5

3

4

3
1

Fatty Acid Metabolism

2

Oxidative Phosphorylation

3

2

1
5

Interferon Gamma Response

2

Interferon Alpha Response

4

PI3K_AKT_MTOR Signaling

5

2

Mitotic Spindle

4

Reactive Oxygen Species

5

4

E2F Targets

2

G2M Checkpoint

3

Androgen Response

5

Protein Secretion

1

IL2 STAT5 Signaling

3

Unfolded Protein Response

3

5
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Table 5.12- Metabolic pathways by principal component
Pathway

PC1

PC2

PC3

PC4

PC5

PC6

PC7

PC8

PC9

PC10

Aminosugars metabolism

0.76

0.36

0.89

0.94

0.16

0.82

0.92

0.37

0.09

0.99

Ascorbateand Aldarate Metabolism

0.35

0.01

1.00

0.13

1.00

0.73

0.61

0.01

0.96

0.03

Aspartate and asparagine metabolism

0.10

0.00

1.00

0.00

0.01

0.98

0.00

0.78

0.36

0.87

Bile acid biosynthesis

0.96

1.00

0.04

0.96

0.08

0.98

1.00

1.00

0.84

1.00

Butanoate metabolism

0.04

0.00

0.93

0.08

0.02

0.62

0.29

0.87

0.57

0.80

C5-Branched dibasic acid metabolism

1.00

0.54

1.00

1.00

1.00

1.00

0.05

1.00

0.70

0.32

Carbon fixation

0.98

0.75

1.00

1.00

0.14

1.00

0.86

0.76

0.11

0.90

Carnitine shuttle

1.00

1.00

0.67

1.00

0.00

1.00

0.99

0.02

0.48

1.00

Chondroitin sulfate degradation

0.94

0.60

1.00

0.27

1.00

0.13

0.09

0.61

0.12

0.79

De novo fatty acid biosynthesis

0.98

0.83

0.39

1.00

0.00

1.00

0.39

0.83

1.00

1.00

Dynorphin metabolism

1.00

1.00

0.09

1.00

1.00

0.08

1.00

0.54

1.00

0.32

Glycerophospholipid metabolism

0.45

0.90

0.51

0.47

0.00

0.41

0.35

0.30

0.34

1.00

0.14

0.23

0.94

0.01

0.27

0.81

0.49

0.82

0.96

1.00

0.90

0.75

1.00

0.01

0.14

0.64

0.08

1.00

0.61

1.00

Heparan sulfate degradation

0.94

0.60

1.00

0.27

1.00

0.13

0.09

0.61

0.12

0.79

Histidine metabolism

0.70

0.01

0.91

0.89

0.06

1.00

0.61

0.83

0.69

0.97

Limonene and pinene degradation

0.71

0.21

1.00

0.01

1.00

0.41

0.73

0.04

0.38

0.00

Linoleate metabolism

0.91

0.56

0.90

0.44

0.05

0.01

0.18

0.00

0.44

0.49

Lysine metabolism

0.01

0.34

0.80

0.49

0.18

0.60

0.63

0.92

0.99

0.99

Methionine and cysteine metabolism

0.06

0.03

0.98

0.15

0.00

0.87

0.44

0.06

0.71

0.28

Mono-unsaturated fatty acid betaoxidation

0.84

0.46

0.06

1.00

1.00

1.00

1.00

1.00

1.00

1.00

Omega-3 fatty acid metabolism

1.00

0.71

0.21

0.77

1.00

0.08

0.83

1.00

1.00

1.00

Phytanic acid peroxisomal oxidation

0.26

0.15

0.09

1.00

1.00

1.00

0.66

0.54

1.00

0.72

Porphyrin metabolism

0.93

0.83

0.91

0.13

1.00

1.00

0.21

0.60

0.86

0.18

Purine metabolism

0.83

0.18

0.95

0.64

0.35

1.00

0.44

0.59

0.05

0.67

Pyrimidine metabolism

0.35

0.12

0.76

0.39

0.13

1.00

0.30

0.83

0.11

1.00

Saturated fatty acids beta-oxidation

0.70

1.00

0.06

1.00

1.00

0.90

0.55

0.76

0.89

0.90

TCA cycle

0.02

0.22

0.27

0.57

0.49

0.78

0.23

0.01

0.51

0.17

Tryptophan metabolism

0.23

0.90

1.00

0.08

0.00

0.78

0.32

0.40

0.97

0.56

Tyrosine metabolism

0.04

0.01

1.00

0.26

0.27

0.50

0.41

0.44

0.50

0.02

Urea cycle/amino group metabolism

0.10

0.00

0.97

0.70

0.53

0.93

0.84

0.69

0.43

0.97

Valine, leucine and isoleucine
degradation

0.03

0.02

0.86

0.14

0.30

0.74

0.76

0.68

0.83

1.00

Vitamin B3 metabolism

0.53

0.60

0.91

1.00

0.01

0.89

0.39

0.07

0.06

0.74

Vitamin K metabolism

0.60

1.00

0.01

1.00

1.00

1.00

1.00

1.00

0.38

1.00

Glycine, serine, alanine and threonine
metabolism
Glyoxylate and Dicarboxylate
Metabolism
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Figure 5.6 Interconnectivity of the top 10 principal components of each dataset
(a) Correlation matrix of the top 10 principal components from gene, protein, and metabolite datasets

Prognostic classifiers from metabolomics and proteomic data
Each protein and metabolite was tested for prognostic significance based on the top quarter, third, and
half of expression. The top 100 metabolites were clustered through K-means clustering to best classify
patients (Figure 5.7A). The two patient cohorts had an extreme difference in prognosis based on this
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new classification (p = 1.59e-5) (Figure 5.7B). Proteins with a maximum log rank p-value of .05 between
these three tests were used. After this filter, 186 proteins remained and those with complete (100%
coverage) were used to cluster patients (Figure 5.7C). While this prognostic signature was not as
significant as the metabolite data, it still had significant difference in overall survival (p = 0.003) (Figure
5.7D).

Figure 5.7 Prognostic signatures from metabolites and proteins
(a) Cluster of the top metabolites prognostically into a high and low risk subset (b) Overall survival of
patients clustered in (a) (c) Cluster of the top proteins prognostically into a high and low risk subset (d)
Overall survival of patients clustered in (c)
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Discussion
In this study we characterize a dataset of lung adenocarcinoma through gene expression microarray, LCMS metabolomics and proteomics, and clinical data containing overall survival. We emphasized analysis
of canonical mutations throughout this study: EGFR, KEAP1, KRAS, STK11, and TP53. Additionally, we
evaluated the dataset in the context of immune signatures for interferon gamma and inflammatory
signaling. The most drastic differences in clinical features resulted from EGFR status. Patients with EGFR
mutations had significantly increased frequency in female gender over male, better prognosis, and were
metabolically characterized by histidine metabolism and histamine production. Furthermore,
heightened inflammatory response predicted from gene expression was significantly enriched for
pyrimidine metabolism and displayed elevated levels of pyridine-2,3-dicarboxylate, nicotinate,
kynurenine, and putrescine. The top 10 unique signatures from principal components of each dataset
were quantified amongst each mutational subtype and immune signature. These signatures were then
correlated to help view the relationship between gene, protein, and metabolite. Finally, from the
proteomics and metabolomics data we generated a prognostic signature. Both were capable of
predicting outcome but the signature from metabolites was superior to that of the protein.
This dataset could be used to generate a number of hypotheses. Individual gene, protein, and
metabolites were not analyzed but rather the decomposition of their matrices through principal
component analysis. The principal component method of matrix decomposition did not capture all the
co-expression networks in this study but rather explained the most variance within the matrix itself.
Future studies could utilize this dataset in order to better understand specific gene-protein-metabolite
relationships or to look for any number of associations. Additionally, post translational modifications of
proteins would add great value to this study should it be performed in the future.
Generation of multi-dimensional molecular data will help us to uncover the complexity that exists within
the development of cancer. Better understanding potential vulnerabilities or ways in which the tumor
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could be influencing the microenvironment can help pave the way for novel therapeutic intervention.
This study helps to analyze lung adenocarcinoma through use of gene, protein, and metabolite data and
allows for the generation of hypotheses worthy of studying further in the lab.
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Chapter 6: Final conclusions and future work

Final conclusions
Lung cancer remains to be the most lethal of any cancer. This work has all been motivated by the sincere
desire to help those affected by this terrible disease, in hopes that through our increase in knowledge
we may one day find a cure.
In this dissertation we display the sheer complexity in the molecular adaptations that occur in cancer
initiation and progression. Various environmental factors, inherited traits, and risk factors all influence
the histology and molecular subtype of cancer as suggested by our study in Chapter 1. However, what is
often overlooked or perhaps blissfully ignored is the difficulty in studying a heterogeneous, adaptive,
and chaotic system in an elaborate environment such as the human body with countless extrinsic
variables. We illustrate in Chapter 2 - 4 the difficulty in studying a single mutation (STK11) outside the
context of the human body.
Classification of STK11 loss in the patient setting is limited by DNA sequencing as only half of all patients
with functional loss are detected as shown in Chapter 2. We developed a novel gene expression based
signature of STK11 loss of function that was validated in two large datasets that can be applied clinically.
Additionally, we provide evidence that KIT could be used as a standalone IHC biomarker of STK11 loss in
Chapter 4. Since KIT is highly associated with NKX2-1 and cell lineage preservation it may also serve as a
more specific marker for lack of immunotherapy response.
STK11 is a prime example of how intricate and interconnected cell state, metabolism, and immune
surveillance are. STK11 loss contributes to stress response and impacts nearly every cancer hallmark.
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STK11 mutations are most commonly found in lung adenocarcinoma and large cell neuroendocrine
carcinoma and are likely due to cell specific function highlighted in Chapter 3. We have shown that
STK11 is associated with increased polyamine metabolism and expression of its rate limiting enzyme
ODC1, a pathway that has been strongly linked to immune suppression seen in Chapter 2. We believe
that STK11 loss in the patient tumor is contributing to immune evasion through the cell lineage specific
conversion of putrescine to GABA through the enzymes MAOA and ALDH3A2 and that this immune
suppression could be partially if not completely eliminated through ODC1 inhibition by DFMO.
In Chapter 5 we relate untargeted LS-MC proteomic and metabolic data to gene expression microarray,
providing novel insight to the relationship that each of these have to one another. We also discover
novel prognostic markers in this cohort that could be useful in a clinical setting. This data will be very
useful for hypothesis generation and even uncovering vulnerabilities or dependencies related to a
genetic phenotype.
I hope that this work allows for the continuation and expansion of our understanding into the molecular
complexity of lung adenocarcinoma. With immunotherapy providing remarkable responses in the small
few that reap its benefit, I hope that this work may increase the number of those that respond even
further. This dissertation has highlighted the great need for personalized medicine in a disease that has
taken so many lives. Cancer is constantly adapting and evolving and so must our technology and
understanding of how to combat it. Through countless decades of research and the collaboration of the
brightest minds may we one day put an end to this disease once and for all.
Future work
This dissertation helped to characterize various aspects of lung adenocarcinoma biology, including the
impact that STK11 loss has on metabolism, immune surveillance, and cell lineage transition. While these
are all very important it generates even more questions left to be answered.
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One interesting experiment that would circumvent the lack of model system would be to deal directly
with fresh patient tumor surgical resections. These tumors could be analyzed using flow cytometry for
the distinguishing markers seen in vivo such as: NKX2-1, KIT, CALCA, ASCL1, and PD-L1. One interesting
question would be to quantify the heterogeneity that exists within a patient tumor and to determine
which cell type was contributing to changes in metabolism and gene expression through LC-MS and
RNA-seq respectively. Patient tumors could be profiled additionally for immune cell infiltrates to
characterize the immune cell populations that exist within each tumor and their respective expression
patterns. Tumor cells with STK11 loss could be sorted into classical, neuroendocrine, and negative
subsets as described in Chapter 3. The sorted cell populations could be further divided to profile
intracellular metabolites and gene expression. This information would provide much greater insight into
the heterogeneity within patient tumors and the contribution of distinct cell populations.
While this aspect of studying patient tumors is vital, it limits our ability to manipulate various aspects of
tumor biology through experimentation. Given the known limitation of cell line, patient derived
xenograft, and mouse models of STK11 loss future studies should focus on directly targeting NKX2-1
positive type II pneumocytes for Cre induced STK11 deletion. Untargeted STK11 deletion of lung cells
resulted in tumors that were of squamous lineage [30, 152]. In addition, mice should be exposed to
chronic tobacco smoke in order to recapture the environmental conditions present in the initiation of
human lung adenocarcinoma. Assuming that this model accurately mimicked patient tumor biology, it
would be fascinating to give mice labeled ornithine and measure the respective metabolites produced
downstream. If GABA and succinate are labeled, it would prove that ornithine is being used as a
precursor for GABA synthesis and TCA cycle intermediates.
Another area of future research would be to assess the impact that metabolites associated with STK11
loss have on various immune cell populations. Distinct immune cells such as antigen presenting
dendritic cells, cytotoxic t-cells, and others should be screened by a library of STK11 associated
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metabolites. Antigen presentation, anti-tumor response, viability, motility, and cytokine secretion
should be measured through varying assays with this library. This information would provide novel
insight into the impact that metabolites have on distinct mechanisms of immune biology and could
result in the generation of inhibitors targeting their synthesis.
Additional work should also be performed in assessing the impact that ODC1 inhibition through DFMO
treatment has with combination immunotherapy in patients with STK11 loss. These patients currently
do not respond to immunotherapy and have no targeted mechanism for their treatment. We know
about the immunosuppressive nature of the polyamine pathway, the increased production of polyamine
related metabolites in tumors with STK11 loss, and the minimal toxicity associated with DFMO. Given
this evidence, a clinical trial should be initiated to assess the efficacy of this treatment to the current
standard of care.
The final area of work that could be done is the successful cloning of NKX2-1 into cell line constructs
with the co-transduction of STK11 (Chapter 4). STK11 appears to have a very intricate relationship to
NKX2-1 and its signaling pathway, which also has neurological roots and has been shown to influence
GABAergic signaling [26, 30, 67, 191]. We had noticed in previous work that the cell line NCIH1437 had
a very distinct pattern of SFTPB protein expression that was dependent on STK11 status. Further
experimentation into the molecular mechanisms explaining the crosstalk between STK11 and NKX2-1
should be explored. It is likely that NKX2-1 influences hypoxic signaling and the oxidative stress
response given that it is present in both the brain and lung, two organs that depend on very well
regulated oxygen levels. Not only this, but in data not shown NKX2-1 expression is highly associated
with VHL mutations in kidney cancer, suggesting that it plays a role in HIF1A stabilization. Previous
literature has highlighted the role of both AMPK and STK11 on hypoxia and oxygen sensing [192-194].
This could shed light on the unanimous loss of NKX2-1 in ex vivo models of STK11 loss.
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